Neurotransmitters & networks

Neurotransmitters & Networks

An MR view on epilepsy and antiepileptic drugs

Printed by Gildeprint, Enschede
Cover photo by Huang Yigao, https://unsplash.com/@ikarishinjigao
ISBN: 978-94-6233-644-5

Printing of this thesis was financially supported by Maastricht University and UCB Pharma BV.

Neurotransmitters & Networks

An MR view on epilepsy and antiepileptic drugs

PROEFSCHRIFT

ter verkrijging van de graad van doctor aan de Universiteit Maastricht,
op gezag van de Rector Magnificus, Prof. dr. Rianne M. Letschert
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen
op donderdag 13 juli 2017 om 16.00 uur

door

Tamar Marije van Veenendaal

Geboren 6 maart 1988 te Nijkerk

Promotores:

Prof. dr. ir. W.H. Backes
Prof. dr. A.P. Aldenkamp

Copromotor:

Dr. J.F.A. Jansen

Beoordelingscommissie:

Prof. dr. F.M. Mottaghy (voorzitter)
Prof. dr. E. Achten (Universiteit Gent)
Prof. dr. R.M. Dijkhuizen (Universitair Medisch Centrum Utrecht)
Prof. dr. H.J.M. Majoie
Prof. dr. R.J. van Oostenbrugge

Contents

Chapter 1

General introduction

1

Epilepsy

Epilepsy is a neurological disease which is characterized by unprovoked recurrent seizures, during which the brain shows abnormal and excessive neuronal activity. Causes of epilepsy can be manifold and epilepsy is often distinguished into focal and generalized epilepsy. In focal epilepsy, seizures are caused by focal pathological changes, such as cortical malformations or tumors, while in generalized epilepsy, the seizure threshold is lowered throughout the cortex, often due to genetic defects [1].

A large majority of the patients takes antiepileptic drugs (AEDs) to suppress epileptic seizures [2]. More than twenty different AEDs are currently available which can be used in mono-therapy or in combination (poly-therapy). Other treatment options include neurostimulation such as vagal nerve or deep brain stimulation and the ketogenic diet. Surgical resection of the epileptogenic focus is currently the only treatment to cure epilepsy, albeit very invasive and only possible in a subgroup of patients: those with a localized and known epileptic focus [1].

Epilepsy is often accompanied with cognitive and behavioral problems, such as memory or attentional problems [3, 4]. Cognitive problems might originate in the epilepsy itself (i.e. the seizures or the underlying neuropathology), but also medicinal treatment is known to induce cognitive and behavioral side effects [5, 6].

Using validated screening methods, side effects have been reported in 60-90% of the patients with epilepsy [7]. These side effects are an important factor in the discontinuation of AED treatment [8]. Cognitive side effects, such as mental slowing, are among the most reported side effects [2, 9], but the occurrence and severity vary between the different AED types [10].

MR techniques in epilepsy

Several (imaging) techniques are available to study *in vivo* the effects of epilepsy and epileptic seizures on the brain, such as electroencephalography (EEG), positron emission tomography (PET), and magnetic resonance (MR) imaging and spectroscopy [11]. Magnetic resonance encompasses a variety of techniques that employ nuclear magnetic resonance to assess structural, functional, or chemical properties of tissue. By applying different settings, various tissue contrasts with different information can be obtained.

With MR imaging (MRI), magnetic properties of 1H-atoms are manipulated to acquire images, while with MR spectroscopy (MRS), chemical information (of organic molecules) is obtained from a local region. MRS enables concentration measurement of different neurometabolites (Table 1.1). Information about brain function can for instance be obtained with task-related functional MRI. Functional

Table 1.1. Commonly detected neurometabolites [14, 15]. The exact function of most metabolites is still not completely understood and metabolites can have other, unknown functions.

Neurometabolite	Function	Marker for
γ-aminobutyric acid (GABA)	Inhibitory neurotransmitter	Level of tonic inhibition (i.e. constant inhibitory activity)
Choline (Cho)	Component of cell membranes	Neurodegeneration/ inflammation, total membrane content
Creatine (Cr)	Storage form of energy (ATP buffer)	Energy metabolism
Glutamate	Excitatory neurotransmitter, involved in glucose metabolism	Metabolic activity
myo-Inositol (mI)	Osmolyte, Involved in cell growth, storage form of glucose, not well understood	Osmotic stress/edema, neurodegeneration
N-acetyl aspartate (NAA)	Osmolyte, not well understood	Neuronal density, neuronal integrity

MRI measures blood oxygen levels, and thereby indirectly brain activity when performing a task or receiving stimuli. By comparing this activity with and without a task or stimulus, areas involved in this task or stimulus perception can be distinguished.

Both MRI and MRS are currently being applied in patients with epilepsy. MRI is commonly applied during clinical diagnosis of patients, for instance to find (structurally visible) epileptogenic lesions [12]. Both MRS and fMRI are mainly used for research purposes. Clinically, MRS is being applied in the diagnosis of metabolic syndromes and tumor characterizations [13], while fMRI can be used to map specific brain functions to aid the pre-surgical planning [12].

Brain connectivity

The human brain consists of more than 10^{11} neurons and 10^{14} connections, called synapses, linking these neurons [16]. If a neuron is active, an action potential travels through the neuron and when this action potential reaches the synapse, neurotransmitters are released (Figure 1.1). These neurotransmitters induce a signal in the connected neuron, which can in- or decrease the probability of an action potential in that neuron. Several chemical substances may act as neurotransmitters, including glutamate and γ-aminobutyric acid (GABA), which are the most abundant excitatory and inhibitory neurotransmitters in the central nervous system, respectively. Other neurotransmitters are important in several brain diseases but are less abundant, such as dopamine, which is affected in Parkinson's disease, or serotonin, important in mood disorders [16].



Figure 1.1. Basic mechanism in a synapse. If the presynaptic neuron is active, neurotransmitters are released. Neurotransmitters bind to receptors at the postsynaptic neuron, inducing a signal in that neuron.

Epilepsy, including focal epilepsy, is hypothesized to be a 'network disease', indicating that not one single region is involved in seizure generation and propagation, but rather that it involves the interplay between different brain regions [17, 18]. Epileptic seizures are hypothesized to result from disbalances within these neuronal networks, either because of increased (or decreased) excitatory (or inhibitory) neurotransmission, changes in connectivity, or altered neuronal cell properties [1]. AED treatment targets the dynamic processes that affect this disbalance [19].

Because brain regions are connected, seizure activity might also affect brain structures distant from the seizure focus, even when no seizure activity is present in these structures. Altered brain networks in patients with epilepsy can also explain some of the cognitive problems of these patients, since these networks enable the integration of information, which is essential for complex brain functions [20].

Advanced MR acquisition techniques and analyses methods have been developed which enable assessment of brain networks, for instance fMRI. Besides evaluating brain activity, fMRI can also be used to assess functional connectivity [21, 22]. This connectivity is defined as correlated brain activity, i.e. 'neurons that fire together, wire together' [23]. Several studies have shown a disrupted functional connectivity and organization of brain networks in patients with epilepsy [19], which furthermore appeared to be associated with cognitive decline in epilepsy [21, 22]. However, medication-effects were out of scope in most of these studies, while AED treatment is also an important cause of cognitive problems in patients with epilepsy [5]. In the first part of this thesis, we therefore focused on these medication effects.

Aim and outline of this thesis

The aim of this thesis was to further assess associations of brain connectivity and cognitive problems in epilepsy. Therefore, two goals were formulated:

1. To identify neuronal substrates of cognitive side effects of antiepileptic drugs using magnetic resonance;
2. To explore and evaluate novel MR techniques that may give new insights into epilepsy.

The first, clinical question is described in the first part of this thesis. In Chapter 2, a literature study is presented that elaborates on AEDs in relationship to MR imaging: what are the problems with these drugs, and which possibilities can MR provide to give insights in these problems? Chapter 3 and 4 present the results of an MR study we performed to assess associations between AED use, cognitive problems, and MR biomarkers in patients with chronic epilepsy. In Chapter 3, associations with neurotransmitter levels measured with MRS are described, while Chapter 4 describes the associations with functional brain networks measures.

The second part consists of studies of a more methodological nature. Chapter 5 describes and compares two commonly applied MRS methods to measure brain glutamate levels: PRESS and MEGA-PRESS. This chapter presents the accuracy (tested in a phantom experiment), repeatability (evaluated in human participants) and the concordance between the methods (also tested in human participants). In Chapter 6, an ultra-high-field MRS pilot study is described that assesses the spatial coherence between local neurotransmitter concentrations in both healthy volunteers and patients with epilepsy. This chapter presents the concept of 'neurotransmitter networks', a new method to study brain connectivity on the basis of spatial relations in neurontransmitter concentration distributions.

Finally, all results are summarized and discussed in Chapter 7. This chapter also includes recommendations for further research and is finalized with a general conclusion.

References

[1] J. S. Duncan, J. W. Sander, S. M. Sisodiya, and M. C. Walker. Adult epilepsy. *The Lancet*, 367 (9516):1087–1100, 2006.

[2] R. S. Fisher, B. G. Vickrey, P. Gibson, B. Hermann, P. Penovich, A. Scherer, and S. Walker. The impact of epilepsy from the patient's perspective II: views about therapy and health care. *Epilepsy Research*, 41(1):53–62, 2000.

[3] R. S. Fisher, B. G. Vickrey, P. Gibson, B. Hermann, P. Penovich, A. Scherer, and S. Walker. The impact of epilepsy from the patient's perspective I. descriptions and subjective perceptions. *Epilepsy research*, 41(1):39–51, 2000.

[4] C. E. Elger, C. Helmstaedter, and M. Kurthen. Chronic epilepsy and cognition. *The Lancet Neurology*, 3(11):663–672, 2004.

[5] P. Kwan and M. J. Brodie. Neuropsychological effects of epilepsy and antiepileptic drugs. *The Lancet*, 357(9251):216–222, 2001.

[6] B. Hermann, K. J. Meador, W. D. Gaillard, and J. A. Cramer. Cognition across the lifespan: antiepileptic drugs, epilepsy, or both? *Epilepsy Behav*, 17(1):1–5, 2010.

[7] P. Perucca and F. G. Gilliam. Adverse effects of antiepileptic drugs. *The Lancet Neurology*, 11 (9):792–802, 2012.

[8] H. P. Bootsma, L. Ricker, Y. A. Hekster, J. Hulsman, D. Lambrechts, M. Majoie, A. Schellekens, M. de Krom, and A. P. Aldenkamp. The impact of side effects on long-term retention in three new antiepileptic drugs. *Seizure*, 18(5):327–331, 2009.

[9] S. G. Uijl, C. S. Uiterwaal, A. P. Aldenkamp, J. A. Carpay, J. C. Doelman, K. Keizer, C. J. Vecht, M. C. de Krom, and C. A. van Donselaar. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. *Seizure*, 15(4): 242–8, 2006.

[10] D. M. IJff and A. P. Aldenkamp. *Comorbidities of treatment with antiepileptic drugs*, pages 424–36. New York: McGraw-Hill Professional, 2012.

[11] M. Richardson. Current themes in neuroimaging of epilepsy: brain networks, dynamic phenomena, and clinical relevance. *Clin Neurophysiol*, 121(8):1153–75, 2010.

[12] E. Achten. *Het gebruik van medische beeldvorming bij epilepsie*, pages 25–36. Diagnosis Uitgevers, Leusden, 2015.

[13] G. Öz, J. R. Alger, P. B. Barker, R. Bartha, A. Bizzi, C. Boesch, P. J. Bolan, K. M. Brindle, C. Cudalbu, and A. Dinçer. Clinical proton MR spectroscopy in central nervous system disorders. *Radiology*, 270(3):658–679, 2014.

[14] C. D. Rae. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. *Neurochem Res*, 39(1):1–36, 2014.

[15] V. Govindaraju, K. Young, and A. A. Maudsley. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR in Biomedicine*, 13(3):129–153, 2000.

[16] E. R. Kandel, J. H. Schwartz, and T. M. Jessell. *Elementary interactions between neurons: synaptic transmission*, volume 4, pages 173 – 308. McGraw-hill New York, 2000.

[17] S. S. Spencer. Neural networks in human epilepsy: evidence of and implications for treatment. *Epilepsia*, 43(3):219–227, 2002.

[18] B. C. Bernhardt, L. Bonilha, and D. W. Gross. Network analysis for a network disorder: The emerging role of graph theory in the study of epilepsy. *Epilepsy Behav*, 50:162–70, 2015.

[19] M. A. Rogawski and W. Loscher. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci*, 5 (7):553–64, 2004.

[20] H. J. Park and K. Friston. Structural and functional brain networks: from connections to cognition. *Science*, 342(6158):1238411, 2013.

[21] M. P. van den Heuvel and H. E. Hulshoff Pol. Exploring the brain network: a review on resting-state fMRI functional connectivity. *Eur Neuropsychopharmacol*, 20(8):519–34, 2010.

[22] S. M. Smith. The future of fMRI connectivity. *NeuroImage*, 62(2):1257–66, 2012.

[23] S. Lowel and W. Singer. Selection of intrinsic horizontal connections in the visual cortex by correlated neuronal activity. *Science*, 255(5041):209, 1992.

Part I

Clinical studies

Chapter 2

Metabolic and functional MR biomarkers of antiepileptic drug effectiveness

T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, P. A. M. Hofman, M. C. G. Vlooswijk, R. P. W. Rouhl, A. J. A. de Louw, W. H. Backes, J. F. A. Jansen, *Neuroscience and Biobehavioral Reviews 2015; 59: 92–99*, DOI: 10.1016/j.neubiorev.2015.10.004

Abstract

As a large number of patients with epilepsy do not respond favorably to antiepileptic drugs (AEDs), a better understanding of treatment failure and the cause of adverse side effects is required. The working mechanisms of AEDs also alter neurotransmitter concentrations and brain activity, which can be measured using MR spectroscopy and functional MR imaging, respectively. This review presents an overview of clinical research of MR spectroscopy and functional MR imaging studies to the effects of AEDs on the brain. Despite the scarcity of studies associating MR findings to the effectiveness of AEDs, the current research shows clear potential regarding this matter. Several GABAergic AEDs have been shown to increase the GABA concentration, which was related to seizure reductions, while language problems due to topiramate have been associated with altered activation patterns measured with functional MR imaging. MR spectroscopy and functional MR imaging provide biomarkers that may predict individual treatment outcomes, and enable the assessment of mechanisms of treatment failure and cognitive side effects.

Introduction

Despite the introduction of several antiepileptic drugs (AEDs) in recent decades, a large number of patients with epilepsy do not respond favorably to AEDs. Ideally, AED usage results in complete seizure freedom, without any unwanted side effects. However, 20-30% of the patients are drug resistant (or, synonymous, medically refractory), i.e. they do not reach seizure freedom after two adequately chosen, dosed and tolerated AEDs [1]. Furthermore, many patients suffer from unwanted side effects, even though the newer generation AEDs is suggested by pharmaceutical companies to have a more beneficial tolerability profile. Today, approximately 10-40% of the patients with epilepsy report side effects spontaneously or in (unstructured) interviews, while 60-90% of patients have been reported to suffer from side effects using validated screening methods [2]. The low effectiveness, i.e. the low combined efficacy and tolerability, results in early treatment discontinuation, high disease burden, and increased health care costs [2, 3]. Considering the need for improvement of the effectiveness, a better understanding of the mechanisms of drug resistance and the cause of side effects is highly desired. This knowledge might, in future, aid the realization of an objective, tailored choice of a specific AED in the individual patient.

Knowledge of the *in vivo* working mechanisms of AEDs is essential to understand drug resistance and side effects. Currently, most AEDs are discovered using animal screening models, in which the anticonvulsant effect of a compound is tested, prior to the exploration of the precise mechanisms of action [1, 4]. Animal models are used to test for efficacy [1] and side effects [5]. The molecular mechanisms of action are assessed at a later stage using *in vitro* research, including studies in neuronal cell cultures, patch-clamp measurements, and biochemistry [6]. These studies have resulted in some basic understanding of the different molecular mechanisms of the available AEDs. However, it still remains difficult to relate these mechanisms of action to the anticonvulsant effect of an AED in patients, mainly because the anticonvulsant effect is also influenced by the pharmacokinetic properties of the compound, such as its ability to cross the blood brain barrier or its metabolism [4, 7]. Furthermore, the complexity of the brain limits a straightforward translation of *in vitro* effects of isolated neuronal cells to *in vivo* effects. Finally, *in vitro* or animal studies cannot completely assess potential side effects on cognition, which can only present themselves after administration in human subjects. Therefore, there is a need for alternative techniques that can assess the effects of AEDs on human brains.

Clinically, magnetic resonance imaging (MRI) is commonly used to provide anatomical information. These anatomical scans are also applied to assess effects

of AEDs on for instance brain volume or cortical thickness [8, 9]. However, there are also MR techniques available that provide information beyond the anatomy, such as metabolism and function, which expectedly are more sensitive to AED treatment. MR spectroscopy (MRS) enables *in vivo* measurements of neurotransmitter and other brain metabolite concentrations, and can therefore be employed to gather insight in the metabolism of AEDs [10, 11]. Another technique is functional MRI (fMRI), which can provide a measure of drug effects on brain activity [12]. These MRI assessments are noninvasive, which makes them suitable for repeated measurements, as no contrast agents or ionizing radiation are necessary, in contrast to other imaging techniques such as computed tomography (CT) or positron emission tomography (PET).

An overview of the previous MRS and fMRI studies to the effects of AEDs on the brain is presented in this review. These MR techniques are sensitive to brain metabolism and function, respectively, which are both directly related to the AED mechanisms of action. Special attention is paid to the possible relation of MR measures with drug resistance and central nervous system (CNS) mediated side effects of AEDs.

Methods

A literature study was performed in Medline/PubMed on August 7, 2015, using the Medical Subject Headings (MeSH) 'anticonvulsants', 'Magnetic Resonance Spectroscopy' and the terms 'functional MRI' or 'fMRI' and 'treatment failure'. Additionally, separate searches were performed per individual AED (the considered AEDs are listed in Table 2.1).Furthermore, relevant references from the reviewed articles are included. Only articles written in English and performed in human subjects are considered. The abstracts of the resulting articles were screened to select only the relevant articles, i.e. articles describing effects of AEDs detectable with MRI, or relating MRI outcomes to seizure reduction or side effects. Studies describing the effects of AEDs in patients with other types of disorders than epilepsy were omitted, because of potential differences in working mechanisms in different diseases, and unknown effects of comorbidities. Studies comparing patients with epilepsy using AEDs to healthy controls not using these AEDs were also omitted, because the effect of the epilepsy itself and drug use cannot be distinguished in these studies.

Table 2.1. Molecular targets of anti-epileptic drugs [13–17].

	Voltage-gated ion channels[a]	Neurotransmitter systems[a]
Benzodiazepines:		GABA system
Clobazam		
Clonazepam		
Midazolam		
Diazepam		
Carbamazepine	Na^+	
Ethosuximide	(Na^+), Ca_2^+	
Felbamate	Na^+, Ca_2^+	GABA system, glutamate receptors
Gabapentin	(Na^+, Ca_2^+)	GABA system
Lacosamide	(Na^+)	Glutamate receptors
Lamotrigine	Na^+, (Ca_2^+)	
Levetiracetam	Ca_2^+	(GABA system, glutamate receptors)
Oxcarbazepine	Na^+, (Ca_2^+, K^+)	
Phenobarbital	Ca_2^+	GABA system, (glutamate receptors)
Phenytoin	Na^+	
Pregabalin	Ca_2^+	
Retigabine	K^+	GABA system
Stiripentol		GABA system
Tiagabine		GABA system
Topiramate	Na^+, Ca_2^+	GABA system, glutamate receptors
Valproate	(Na^+, Ca_2^+)	GABA system, glutamate receptors
Vigabatrin		GABA system
Zonisamide	Na^+, Ca_2^+	

[a]Not all molecular mechanisms are well understood; possible molecular targets are displayed between parentheses.

Pharmacodynamic and pharmacokinetic mechanisms of action

Epileptic seizures are characterized by excessive, synchronal neuronal activity in the brain. AEDs, ideally, suppress this activity via several distinct mechanisms, which can be divided into three main categories: 1) Modulation of the voltage-gated ion channels, i.e. of the sodium or calcium channels, and, less common, of the potassium channels. This modulation can result in a more stable membrane potential, reduced release of neurotransmitters, and a reduction in seizure spread. The exact effects of this modulation depend on the specific channel type. 2) Elevation of the seizure threshold by targeting the γ-aminobutyric acid (GABA) system. The GABA system can be affected by two mechanisms: by increasing the sensitivity of the $GABA_A$ receptors or by augmenting the GABA concentration. 3) Reduction of the excitatory neurotransmission. AEDs with the latter mechanism

function as antagonists of the glutamate receptors [15, 17]. Several AEDs combine different mechanisms, and the mechanisms are not completely understood for all AEDs (Table 2.1).

In addition to these pharmacodynamic mechanisms, pharmacokinetic properties contribute greatly to the positive and negative effects of AEDs. Pharmacokinetic properties include the absorption, distribution, metabolism, and excretion of a compound. These factors can differ among different users and with different AEDs, and complicate the prediction of the efficacy and the tolerability in individual patients [18].

Unfortunately, the mechanisms that aim to suppress epileptic seizures can also affect normal brain activity. Modifying these mechanisms can also induce side effects. These CNS mediated side effects include sedation, coordination disturbances, cognitive difficulties, and behavioral problems. Although the probability and severity of these side effects depend on the AED type, several of these events are quite similar among the different AEDs [2]. Also several non-CNS mediated side effects can occur with the use of AEDs, which might result from pharmacokinetic properties, interaction effects, or effects on other organ systems and the immune system (allergic reactions) [2, 3].

Treatment failure is defined as the appearance of recurrent seizures after adequate intervention [19]. Treatment failure in previous AEDs is a strong indicator of treatment failure for new AEDs: While approximately 62% of the patients became seizure free after the first, adequately chosen AED, only 17% of the patients became seizure free after failure of two to five adequately chosen AEDs in a cohort study of 478 patients with newly administered AEDs and various epilepsy types [20]. The mechanisms of treatment failure and drug resistance are also still largely unknown, and both pharmacodynamic and pharmacokinetic properties are likely to be involved in these mechanisms. Several hypotheses have been formulated which explain treatment failure in patients with epilepsy, of which the transporter and the target hypothesis are most popular. The transporter hypothesis argues that AEDs cannot sufficiently penetrate the epileptogenic brain tissue, as a result of increased expression of efflux transporters in the blood-brain barrier. According to the target hypothesis, AEDs are able to reach the ion channels or receptors, but cannot exert their function due to structural and/or functional alterations of these targets. A combination of the above listed hypotheses and other mechanisms (including inflammatory, epigenetic, and also unknown pathways) most likely cooperate in some way to drug resistance in epilepsy [1, 21].



Figure 2.1. A. Example of magnetic resonance spectrum measured in the occipital lobe of a healthy human. The concentrations of NAA, creatine and the choline-containing compounds are relatively high in the brain, resulting in large resonance peaks. Although GABA, glutamate and glutamine are also abundant in the brain, their resonance peaks are much smaller because of spin-spin interactions. The $4\,CH_2$ group of GABA has approximately the same resonance frequency as the $N(CH_3)$ group of creatine and is only measurable using advanced acquisition or analysis methods [22]. The same holds for glutamate and glutamine. B. Estimations by LCModel [23] of the contribution of single molecules to the spectrum displayed in A. Cho: choline-containing compounds; Cr: creatine; GABA: γ-aminobutyric acid; Glu: glutamate; Gln: glutamine; NAA: N-acetyl-aspartate; ppm: parts per million.

Magnetic resonance spectroscopy

AEDs exert their anticonvulsant properties by affecting the excitatory and inhibitory neurotransmitter systems. Effects on the GABA and glutamate concentrations can be measured directly *in vivo* using ^{1}H-MRS (proton MRS). The merit of ^{1}H-MRS is based on the shielding effect of the chemical environment of protons, which causes a small shift in resonance frequency. ^{1}H-MRS results in a spectrum with peaks at different resonance frequencies, characteristic for different molecule groups (Figure 2.1). The area underneath these peaks is proportional to the concentration of the molecule. Whether it is possible to measure a particular metabolite depends on its concentration in the brain, spectral overlap with other metabolites, and spin-spin interactions, which can result in lower resonance peaks [10].

GABA and glutamate both are subject to spectral overlap and spin-spin interactions (Figure 2.1). Special editing techniques or 2D ^{1}H-MRS are commonly used to resolve this problem [10, 24]. These techniques enable a reliable estimation of the concentration of the metabolites [24]. Due to their overlapping resonances,

the glutamate and glutamine concentrations are frequently combined, resulting in a so-called 'Glx' concentration. Other metabolites which are commonly measured using ^{1}H-MRS include N-acetyl aspartate (NAA), creatine or choline-containing compounds. The functions of these metabolites are elaborately discussed elsewhere [22, 25].

Several AEDs with a GABAergic mechanism of action have been shown to elevate GABA concentrations in the brain, including vigabatrin (VGB) [26–32], topiramate (TPM) [33–36] and gabapentin (GBP) [34, 37–39] (Figure 2.2). Elevated GABA concentrations were already detectable within hours after intake of a single dose and also appeared during chronic VGB, TPM and GBP use, although no effects of a single low dose GBP on the GABA concentration were found by Preuss et al. [40]. There is a linear relation between the VGB dosage and the resulting GABA concentration. However, with high VGB dosages, the GABA concentration does not increase any further and reaches a plateau [41]. The GABA concentration was related to seizure reduction in patients with focal epilepsy with VGB [42] and GBP use [39]. Moreover, a relation was found between seizure reduction and the GABA concentration before and during VGB treatment in patients with poorly controlled focal epilepsy [43]. Patients with focal epilepsy with complete seizure control had a lower baseline GABA concentration in the epileptic hemisphere, compared with the non-epileptic hemisphere, and a significant increase of GABA. However, patients with no VGB-induced seizure reduction did not reveal concentration differences between the hemispheres or a significant increase in GABA concentration. The pretherapeutic concentration differences between the hemispheres correlated with the seizure reduction during VGB treatment [44]. These results suggest a causal relation between GABAergic mechanisms of action, the increase in GABA concentration, and seizure reduction. However, this causal link cannot be proven using these radiological techniques in human studies.

In contrast to these results, no effects of a single dose of tiagabine (TGB) on the GABA concentration were found in healthy participants by Myers et al. [45], although TGB is an AED with a solely GABAergic mechanism of action as well. Generalizations across the different AEDs should be considered with caution, because the mechanism of action each individual AED is unique even for chemically related AEDs.

The effects of levetiracetam (LEV) on the GABA concentration are not clear. The mechanisms of action of LEV are not completely understood but according to literature it has probably multiple mechanisms of action, including a GABAergic mechanism [15]. While one study showed a significant increase in the GABA concentration after LEV use in patients with focal epilepsy who had a seizure reduction [46], another study failed to show effects on the GABA concentration in



Figure 2.2. Graphs illustrating the effect of topiramate on the GABA concentration, as measured with MR spectroscopy. A. Serial GABA spectra of a patient with epilepsy before and after use of topiramate. This spectrum, measured using a special editing technique, shows an increase in GABA concentration in an individual patient [Reprinted from Petroff et al. [35]]. B. Time changes of the GABA concentrations (dashed line) and serum topiramate (TPM, solid line) levels before and during TPM use [Reprinted from Kuzniecky et al. [34]]. The GABA concentration is significantly increased compared with the baseline concentration during TPM use. *: $p<0.001$, **: $p<0.006$, ***: $p<0.002$, ****: $p<0.005$. GABA: γ-aminobutyric acid; ppm: parts per million, h: hours, w: weeks

healthy participants [47]. Besides the difference in participants (patients with focal epilepsy versus healthy people), this difference might be explained by the timing of the measurements: the MRS measurements were performed before and 2-6 weeks after initiation of LEV treatment in the patients with epilepsy, while the measurements were performed before, at 3 and at 6 hours after a single dose of LEV in the healthy participants. The effect on the GABA concentration of AEDs without a known GABAergic mechanism of action is rarely assessed. However, elevated GABA concentrations are shown in healthy participants with lamotrigine (LTG) use, albeit only after four weeks use and not directly after a single dose or after 2 weeks of LTG usage, implying that the GABA concentration is increased by indirect effects of LTG [34].

Also the effects of AEDs on the homocarnosine and pyrrolidine metabolites were assessed. These metabolites are precursors of GABA and have been suggested to have anticonvulsant properties themselves [48]. The homocarnosine and pyrrolidine concentrations were shown to increase with the use of TPM [35, 36], VGB [28, 49] or GBP [38]. The authors suggested that homocarnosine (and not GABA) is associated with seizure reduction in patients with focal epilepsy using TPM and GBP [50], using VGB [49], or in a group of patients with focal epilepsy or juvenile

myoclonic epilepsy using valproate (VPA) or LTG [51].

The effects of AEDs on the glutamate concentration are also not clear. Articles assessing the effects of GBP [37, 40], benzodiazepines [52, 53], VPA [54], or TPM [55] on the glutamate, glutamine, or Glx concentration failed to show consistent results. In contrast to the GABAergic mechanisms, AEDs do not alter the glutamate concentrations directly, but rather decrease the sensitivity of the glutamate receptors. The glutamate concentration might be decreased through the negative modulation of the voltage-gated channels, which are affected by most of the AEDs.

Indirectly, AEDs might also affect the concentrations of other metabolites. Campos et al. [56] showed decreased NAA concentrations in patients with focal epilepsy who did not respond to their AED treatment compared with responders one to two years after initiation of AED therapy. As the NAA concentration is generally associated with neuronal density or integrity, these results suggest that treatment failure can be associated with neuronal damage. The choline concentration did not differ between these responder groups. Furthermore, patients with various types of epilepsy using VPA showed reduced myo-inositol concentrations compared with patients taking other AEDs, but similar NAA and creatine concentrations [54, 57]. The authors argue that the myoinositol reductions are not likely to be related to the antiepileptic efficacy of VPA. In healthy participants, no changes in the NAA or choline concentrations were measured after GBP intake [40], and also lorazepam intake did not affect the NAA, creatine, myoinositol, or trimethylamine concentrations [52].

Effects on neurotransmitter concentrations can also be measured in animal models. However, the results of animal studies do not always correspond to human studies. For instance, the effect of TPM on the GABA concentration was not predicted by animal models [35]. Moreover, homocarnosine concentrations are much lower in rodents compared to humans, while homocarnosine is suggested to be involved in the anticonvulsant mechanisms [35]. The results of Kuzniecky et al. [34], showing long-term elevations of GABA after LTG use, illustrate that also AEDs without a known GABAergic mechanism can (indirectly) alter the GABA concentrations. This necessitates human *in vivo* measurements.

Functional MRI

fMRI uses the blood oxygen level dependent (BOLD) effect to indirectly measure brain activity. By comparing the BOLD signal of a baseline condition to a situation with a task, an activity measure for the brain areas involved in this task can be obtained [12]. BOLD measurements can also be performed without a certain

task. This so-called resting state fMRI measures the spontaneous fluctuations of the ongoing neural signaling. The spontaneous fluctuations show correlations between several distinct brain areas, and these correlations are assumed to reflect intrinsic functional connections. Advanced analysis techniques, such as independent component analysis or graph theory, can be applied to assess the functional brain connectivity [58].

It is plausible to assume that AEDs, by suppressing the epileptiform activity, also affect normal brain activity and thereby the BOLD signal. Different brain areas might be more susceptible to AED actions compared with other regions, as AEDs exert their function on specific receptors which might be more prominent in specific brain areas than other. fMRI can be used to identify these altered activation patterns in relation to CNS-mediated side effects or treatment failure.

Several studies employing task fMRI indeed show that AEDs have different effects on brain activation patterns in healthy participants [59–65] or in patients with drug resistant temporal lobe epilepsy [66]. These effects vary among AEDs [67, 68] and depend on the specific task performed during the measurements [69]. While AEDs mainly attenuate the activation patterns, as can be expected from their mechanisms of action, also enhanced activation during AED use has been reported [70]. This seemingly contradictory result could be an indirect effect of attenuated activation in other brain areas, or result directly from AED mechanisms, as a computer simulation showed that modulation of the sodium channels by phenytoin or carbamazepine can also lead to increased excitation [71].

Using graph analysis, a lower hubness (the presence of hyperconnected nodes that connect distant parts of the brain) was found in patients with temporal lobe epilepsy using carbamazepine or oxcarbazepine compared with patients using other AEDs, implying a less efficient organization [72]. Relating these findings to anticonvulsant mechanisms or the development of CNS mediated side effects was outside the scope of these articles.

Other studies assessed associations between cognitive side effects, brain activation and TPM, which induces cognitive side effects including language disturbances [14]. In a study comparing patients with cryptogenic (i.e. with unknown cause) focal drug resistant epilepsy using TPM with patients using other AEDs, several language areas appeared to be significantly underactivated during a language task in the patients using TPM (Figure 2.3). Decreased activation in these areas was also correlated to the language problems [73]. Similar results were found in patients with migraine treated with TPM [74]. Another study found comparable differences in brain activation between patients with temporal lobe epilepsy using TPM and patients using other AEDs, although the observed differences also depended on the lateralization of the epileptic focus [75]. Besides effects in lan-



Figure 2.3. Activations maps of a group of patients with cryptogenic focal epilepsy using topiramate (TPM, n=5, right) versus patients using other AEDs (n=10), obtained using a covert word generation paradigm [Reprinted from Jansen et al. [73]]. These activation maps show a significantly underactivation in the language areas in patients using topiramate compared with other patients. L: left.

guage areas, patients with frontal lobe epilepsy taking TPM showed a reduced deactivation of the default mode network [76]. The default mode network consists of functionally connected brain areas which are active during rest, but deactivate during tasks. Appropriate deactivation of this network is considered necessary for correct task performance.

In contrast to TPM, LEV does not negatively affect cognitive abilities, and is even suggested to improve cognitive function [14]. Patients with temporal lobe epilepsy taking LEV showed more deactivations in the ipsilateral mesial temporal structures compared with patients using other AEDs during working memory tasks [77]. Stronger deactivation in these structures is commonly associated with improved functioning [77]. Whether this reduction was also associated with better cognitive functioning in this study was not reported.

Treatment failure is hypothesized to be caused by alterations of the blood-brain barrier or the molecular targets of the AEDs [1]. Because of these alterations, AEDs cannot exert their function in the epileptogenic brain tissue. However, the location of this epileptogenic brain tissue varies largely between patients, while fMRI is mainly employed to assess the susceptibility of distinct brain areas to the effects of AEDs. In case fMRI experiments are combined with knowledge about the epileptic focus, fMRI might provide new information about mechanisms of action.

Interestingly, Kay et al. [78] also showed associations between treatment resistance and functional connectivity. Patients with idiopathic generalized epilepsy resistant to AEDs showed a reduced connectivity in the default mode network

compared with patients who did show a seizure reduction. Whether this is a consequence of the drug resistance (i.e. the continuing seizures) or is preceding the drug resistance remains unknown.

Limitations

The application of MR techniques in AED treatment is still in its infancy, and several research gaps need to be bridged before these techniques can prove their clinical utility. Currently, the number of MR studies assessing the effects of AEDs is limited, and only a few studies relate MR outcomes to either seizure reduction or CNS mediated side effects. Furthermore, many of the included articles have low participant numbers and have to deal with practical constraints such as polytherapy and possible confounding effects of the epilepsy itself, limiting the quality of these studies.

Beside these general study limitations, the different MR techniques also have some limitations. The interpretation of ^{1}H-MRS findings is currently debated [79, 80]. ^{1}H-MRS measures all available neurotransmitters: both synaptically and extrasynaptically (presynaptic terminals, synaptic vesicles or neurotransmitter uptake mechanisms), and it is not known where and how these neurotransmitters act precisely [79]. ^{1}H-MRS is also only able to measure the neurotransmitter concentrations but not the receptor sensitivity, while this sensitivity is affected by AEDs in particular and could be crucial for effectiveness. Furthermore, the neurotransmitter concentrations are usually measured in a large, single voxel located in the occipital brain regions, whereas the majority of the side effects concerns functions dependent on other brain regions. The use of smaller voxels or voxels located in those other brain areas is limited by the signal-to-noise ratio (SNR) and magnetic field inhomogeneities.

Moreover, most AEDs exert their anticonvulsant activity using several mechanisms, and the interaction between these mechanisms is largely unknown. Only analyzing the effects of the AEDs on the GABA concentration might therefore be too simplistic. Although currently not many effects of AEDs on the glutamate concentrations are shown, it is recommended to measure this concentration as well to have an indication of the balance between the main inhibitory and excitatory mechanisms.

No general conclusions can be drawn about the specific effects of AEDs on the brain activity. Most fMRI studies are performed with specific tasks, and the results of these studies are difficult to generalize because of their task-dependency. Another drawback of fMRI studies is that some AEDs might affect the blood flow and thereby the BOLD signal, irrespective of their antiepileptic effect. These effects

should be considered in future fMRI studies to AEDs. For instance, fMRI studies can be combined with arterial spin labeling measurements, to measure the blood flow [81].

Perspectives

Despite these limitations, both MRS and fMRI results show potential promising applications in future AED research. The suggested relation between GABAergic mechanisms of action, the GABA concentration measured using MRS, and seizure reduction implies several possibilities. First, the GABA concentration can be used as a biomarker for seizure reduction, enabling an earlier indication of treatment failure than clinical evaluation. Furthermore, MRS might provide insights in the development of CNS mediated side effects. The mechanisms responsible for this development still remain largely unknown, although some studies hypothesize that GABAergic mechanisms are involved [5, 73]. By providing a tool to measure the effects of these GABAergic mechanisms, MRS might indicate whether these mechanisms can indeed be associated with CNS mediated side effects. Therefore, MRS might provide valuable information for the selection of the most suitable AED, or exclusion of AEDs which are less suitable, prior to or soon after initiation of treatment. These potential utilities can only be proven after future suitable studies.

fMRI might be employed to pinpoint the neuronal substrate of the side effects. Abnormal activation patterns could possibly explain in part why some patients experience more and others less CNS mediated side effects, and might even predict this for individual patients. Furthermore, the occurrence of side effects might be predicted for new antiepileptic compounds, if it is known how AED effects on brain activity are associated with these side effects.

New studies should focus on the usefulness of these MR techniques for different types of epilepsy, especially when relating treatment failure to MR outcome. Treatment failure is more common in specific epilepsy syndromes (Ohtahara syndrome, early myoclonic encephalopathy, West syndrome, Dravet syndrome, or Lennox-Gastaut syndrome) and underlying etiologies (hippocampal sclerosis, cortical dysplasia, hemorrhage) [82], and the mechanisms of drug resistance might depend on the specific brain pathology [21]. MRS and fMRI might also be employed to assess the effects of other epilepsy treatments, such as the ketogenic diet, and compare these to AED effects on brain metabolite concentrations or activation patterns [83].

Novel, and more advanced MR technologies offer new opportunities to overcome many of the current limitations. With the use of higher magnetic field strengths, the SNR of MRS can be increased. Smaller voxels, frontally located voxels, and even multivoxel MRS becomes feasible with 7 Tesla MR studies (see for instance Pan

et al. [84]). These studies can increase the knowledge of regional effects of AEDs on the neurotransmitter concentration. Besides ^{1}H-MRS, also ^{13}C-MRS can be employed. This method enables the assessment of neurotransmitter cycling and human brain energetics, although ^{13}C-MRS is less accessible than ^{1}H-MRS due to the low natural abundance of ^{13}C and the need for labeled compounds and special hardware [85]. Furthermore, while MRS does not measure the receptor sensitivity, multimodal studies combining PET and MRS enable assessments of both receptor sensitivity and neurotransmitter concentrations [32]. Finally, contrast-enhanced MRI allows for the assessment of the blood-brain barrier integrity, which could be an important feature of treatment failure [86].

The advanced analysis methods for fMRI data provide opportunities to assess the functional brain connectivity. This functional brain connectivity might be more related to cognition than brain activity patterns [87], and therefore more relevant to assess especially cognitive side effects than task related activity analysis. These methods are often employed in combination with resting state fMRI, thereby also omitting the task-dependence of the results [58].

To conclude, MR techniques provide several unique possibilities to assess neuronal substrates of the effectiveness of AEDs, which might be employed for future individualized patients care. These possibilities are supported by the technological improvements of the last decade, which open new possibilities to apply fMRI and MRS to assess AED mechanisms and effects. However, future studies are still necessary to investigate the potential of the different MR techniques to provide biomarkers, to predict treatment outcome or to assess the mechanisms of treatment failure and side effects.

References

[1] W. Loscher, H. Klitgaard, R. E. Twyman, and D. Schmidt. New avenues for anti-epileptic drug discovery and development. *Nat Rev Drug Discov*, 12(10):757–76, 2013.

[2] P. Perucca and F. G. Gilliam. Adverse effects of antiepileptic drugs. *The Lancet Neurology*, 11 (9):792–802, 2012.

[3] R. Toledano and A. Gil-Nagel. Adverse effects of antiepileptic drugs. *Semin Neurol*, 28(3):317–27, 2008.

[4] M. A. Rogawski. Molecular targets versus models for new antiepileptic drug discovery. *Epilepsy research*, 68(1):22–28, 2006.

[5] R. Sankar and G. L. Holmes. Mechanisms of action for the commonly used antiepileptic drugs: Relevance to antiepileptic drug–associated neurobehavioral adverse effects. *Journal of Child Neurology*, 19(1 suppl):S6–S14, 2004.

[6] M. A. Dichter and J. Pollard. *Models of Seizures and Epilepsy*, chapter Cell Culture Models for Studying Epilepsy, pages 23–34. Elsevier Academic Press, 2006.

[7] M. J. Brodie, A. Covanis, A. Gil-Nagel, H. Lerche, E. Perucca, G. J. Sills, and H. S. White. Antiepileptic drug therapy: does mechanism of action matter? *Epilepsy & Behavior*, 21(4): 331–41, 2011.

[8] F. A. De Marco, E. Ghizoni, E. Kobayashi, L. M. Li, and F. Cendes. Cerebellar volume and long-term use of phenytoin. *Seizure*, 12(5):312–315, 2003.

[9] H. R. Pardoe, A. T. Berg, and G. D. Jackson. Sodium valproate use is associated with reduced parietal lobe thickness and brain volume. *Neurology*, 80(20):1895–1900, 2013.

[10] N. A. Puts and R. A. Edden. In vivo magnetic resonance spectroscopy of GABA: a methodological review. *Prog Nucl Magn Reson Spectrosc*, 60:29–41, 2012.

[11] A. J. Ross and P. S. Sachdev. Magnetic resonance spectroscopy in cognitive research. *Brain Res Rev*, 44(2-3):83–102, 2004.

[12] R. G. Wise and I. Tracey. The role of fMRI in drug discovery. *J Magn Reson Imaging*, 23(6): 862–76, 2006.

[13] J. L. Fisher. The effects of stiripentol on GABA(A) receptors. *Epilepsia*, 52 Suppl 2:76–8, 2011.

[14] P. Kwan and M. J. Brodie. Neuropsychological effects of epilepsy and antiepileptic drugs. *The Lancet*, 357(9251):216–222, 2001.

[15] M. A. Rogawski and W. Loscher. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci*, 5 (7):553–64, 2004.

[16] L. J. Stephen and M. J. Brodie. Pharmacotherapy of epilepsy. *CNS drugs*, 25(2):89–107, 2011.

[17] H. S. White, M. D. Smith, and K. S. Wilcox. Mechanisms of action of antiepileptic drugs. *International review of neurobiology*, 81:85–110, 2007.

[18] C. Johannessen Landmark, S. I. Johannessen, and T. Tomson. Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. *Adv Drug Deliv Rev*, 64(10):896–910, 2012.

[19] P. Kwan, A. Arzimanoglou, A. T. Berg, M. J. Brodie, W. Allen Hauser, G. Mathern, S. L. Moshe, E. Perucca, S. Wiebe, and J. French. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. *Epilepsia*, 51(6):1069–77, 2010.

[20] Y. Schiller and Y. Najjar. Quantifying the response to antiepileptic drugs effect of past treatment history. *Neurology*, 70(1):54–65, 2008.

[21] D. Schmidt and W. Loscher. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. *Epilepsia*, 46(6):858–77, 2005.

[22] V. Govindaraju, K. Young, and A. A. Maudsley. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR in Biomedicine*, 13(3):129–153, 2000.

[23] S. W. Provencher. Automatic quantitation of localized in vivo 1H spectra with LCModel. *NMR in Biomedicine*, 14(4):260–264, 2001.

[24] M. E. Henry, T. L. Lauriat, M. Shanahan, P. F. Renshaw, and J. E. Jensen. Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 Tesla. *J Magn Reson*, 208(2):210–8, 2011.

[25] C. D. Rae. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. *Neurochem Res*, 39(1):1–36, 2014.

[26] S. G. Mueller, O. M. Weber, P. Boesiger, and H. G. Wieser. Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy. *Brain research bulletin*, 55(4):555–560, 2001.

[27] E. J. Novotny, F. Hyder, M. Shevell, and D. L. Rothman. GABA changes with vigabatrin in the developing human brain. *Epilepsia*, 40(4):462–466, 1999.

[28] O. A. C. Petroff, F. Hyder, T. Collins, R. H. Mattson, and D. L. Rothman. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. *Epilepsia*, 40(7):958–964, 1999.

[29] O. A. C. Petroff, D. L. Rothman, K. L. Behar, and R. H. Mattson. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of γ-aminobutyric acid, glutamate, and glutamine in human brain. *Epilepsia*, 36(5):457–464, 1995.

[30] O. A. C. Petroff, D. L. Rothman, K. L. Behar, T. L. Collins, and R. H. Mattson. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. *Neurology*, 47(6):1567–1571, 1996.

[31] N. P. L. G. Verhoeff, O. A. C. Petroff, F. Hyder, S. S. Zoghbi, M. Fujita, N. Rajeevan, D. L.

Rothman, J. P. Seibyl, R. H. Mattson, and R. B. Innis. Effects of vigabatrin on the GABAergic system as determined by [123I] iomazenil SPECT and GABA MRS. *Epilepsia*, 40(10):1433–1438, 1999.

[32] O. M. Weber, A. Verhagen, C. O. Duc, D. Meier, K. L. Leenders, and P. Boesiger. Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. *Magnetic resonance imaging*, 17(3):417–425, 1999.

[33] R. Kuzniecky, H. Hetherington, S. Ho, J. Pan, R. Martin, F. Gilliam, J. Hugg, and E. Faught. Topiramate increases cerebral GABA in healthy humans. *Neurology*, 51(2):627–629, 1998.

[34] R. Kuzniecky, S. Ho, J. Pan, R. Martin, F. Gilliam, E. Faught, and H. Hetherington. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. *Neurology*, 58 (3):368–372, 2002.

[35] O. A. C. Petroff, F. Hyder, R. H. Mattson, and D. L. Rothman. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. *Neurology*, 52(3):473–473, 1999.

[36] O. A. C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Topiramate rapidly raises brain GABA in epilepsy patients. *Epilepsia*, 42(4):543–548, 2001.

[37] K. Cai, R. P. Nanga, L. Lamprou, C. Schinstine, M. Elliott, H. Hariharan, R. Reddy, and C. N. Epperson. The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T (1)H-MRS study. *Neuropsychopharmacology*, 37(13):2764–71, 2012.

[38] O. A. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. *Epilepsia*, 41(6):675–80, 2000.

[39] O. A. Petroff, D. L. Rothman, K. L. Behar, D. Lamoureux, and R. H. Mattson. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. *Ann Neurol*, 39(1):95–9, 1996.

[40] N. Preuss, J. W. van der Veen, P. J. Carlson, J. Shen, and G. Hasler. Low single dose gabapentin does not affect prefrontal and occipital gamma-aminobutyric acid concentrations. *Eur Neuropsychopharmacol*, 23(12):1708–13, 2013.

[41] O. A. C. Petroff, D. L. Rothman, K. L. Behar, and R. H. Mattson. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. *Neurology*, 46(5):1459–1459, 1996.

[42] O. A. C. Petroff, K. L. Behar, R. H. Mattson, and D. L. Rothman. Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. *Journal of neurochemistry*, 67(6):2399–2404, 1996.

[43] S. G. Mueller, O. M. Weber, C. O. Duc, B. Weber, D. Meier, W. Russ, P. Boesiger, and H. G. Wieser. Effects of vigabatrin on brain GABA+/Cr signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: Responder characteristics. *Epilepsia*, 42(1):29–40, 2001.

[44] S. G. Mueller, O. M. Weber, C. O. Duc, D. Meier, W. Russ, P. Boesiger, and H. G. Wieser. Effects of vigabatrin on brain GABA+/Cr signals in focus distant and focus near brain regions monitored by 1H-NMR spectroscopy. *European Journal of Neurology*, 10(1):45–52, 2003.

[45] J. F. Myers, C. J. Evans, N. J. Kalk, R. A. Edden, and A. R. Lingford-Hughes. Measurement of GABA using J-difference edited 1H-MRS following modulation of synaptic GABA concentration with tiagabine. *Synapse*, 68(8):355–62, 2014.

[46] M. T. Doelken, T. Hammen, W. Bogner, A. Mennecke, A. Stadlbauer, U. Boettcher, A. Doerfler, and H. Stefan. Alterations of intracerebral gamma-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies. *Epilepsia*, 51(8):1477–82, 2010.

[47] R. Kuzniecky, J. Pan, A. Burns, O. Devinsky, and H. Hetherington. Levetiracetam has no acute effects on brain γ-aminobutyric acid levels. *Epilepsy & Behavior*, 12(2):242–244, 2008.

[48] O. A. C. Petroff. Book review: GABA and glutamate in the human brain. *The Neuroscientist*, 8 (6):562–573, 2002.

[49] O. A. C. Petroff, R. H. Mattson, K. L. Behar, F. Hyder, and D. L. Rothman. Vigabatrin increases human brain homocarnosine and improves seizure control. *Annals of neurology*, 44(6):948–952, 1998.

[50] O. A. C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Brain homocarnosine and seizure control of patients taking gabapentin or topiramate. *Epilepsia*, 47(3):495–498, 2006.

[51] O. A. C. Petroff, F. Hyder, D. L. Rothman, and R. H. Mattson. Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures. *Neurology*, 56(6):709–715, 2001.

[52] P. Brambilla, J. A. Stanley, M. Nicoletti, K. Harenski, K. F. Wells, A. G. Mallinger, M. S. Keshavan, and J. C. Soares. 1H MRS brain measures and acute lorazepam administration in healthy human subjects. *Neuropsychopharmacology*, 26:546–551, 2002.

[53] M. E. Henry, J. E. Jensen, S. C. Licata, C. Ravichandran, M. L. Butman, M. Shanahan, T. L. Lauriat, and P. F. Renshaw. The acute and late CNS glutamine response to benzodiazepine challenge: A pilot pharmacokinetic study using proton magnetic resonance spectroscopy. *Psychiatry Research: Neuroimaging*, 184(3):171–176, 2010.

[54] R. J. Simister, M. A. McLean, G. J. Barker, and J. S. Duncan. The effect of sodium valproate on proton MRS visible neurochemical concentrations. *Epilepsy Res*, 74(2-3):215–9, 2007.

[55] C. M. Moore, M. Wardrop, B. Frederick B. de, and P. F. Renshaw. Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0T magnetic resonance spectroscopy study. *Psychopharmacology (Berl)*, 188(2):236–43, 2006.

[56] B. A. Campos, C. L. Yasuda, G. Castellano, E. Bilevicius, L. M. Li, and F. Cendes. Proton MRS may predict AED response in patients with TLE. *Epilepsia*, 51(5):783–8, 2010.

[57] R. J. Simister, M. A. McLean, G. J. Barker, and J. S. Duncan. Proton MRS reveals frontal lobe metabolite abnormalities in idiopathic generalized epilepsy. *Neurology*, 61(7):897–902, 2003.

[58] M. P. van den Heuvel and H. E. Hulshoff Pol. Exploring the brain network: a review on resting-state fMRI functional connectivity. *Eur Neuropsychopharmacol*, 20(8):519–34, 2010.

[59] R. L. Aupperle, D. Tankersley, L. N. Ravindran, T. Flagan, N. R. Stein, M. B. Stein, and M. P. Paulus. Pregabalin effects on neural response to emotional faces. *Front Hum Neurosci*, 6:42, 2012.

[60] C. M. Del-Ben, C. A. Ferreira, T. A. Sanchez, W. C. Alves-Neto, V. G. Guapo, D. B. de Araujo, and F. G. Graeff. Effects of diazepam on BOLD activation during the processing of aversive faces. *J Psychopharmacol*, 26(4):443–51, 2012.

[61] G. D. Iannetti, L. Zambreanu, R. G. Wise, T. J. Buchanan, J. P. Huggins, T. S. Smart, W. Vennart, and I. Tracey. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. *Proceedings of the National Academy of Sciences of the United States of America*, 102(50):18195–18200, 2005.

[62] X. Li, C. C. Teneback, Z. Nahas, F. A. Kozel, C. Large, J. Cohn, D. E. Bohning, and M. S. George. Interleaved transcranial magnetic stimulation/functional MRI confirms that lamotrigine inhibits cortical excitability in healthy young men. *Neuropsychopharmacology*, 29(7):1395–407, 2004.

[63] Z. Munoz-Torres, J. L. Armony, D. Trejo-Martinez, R. Conde, and M. Corsi-Cabrera. Behavioural and neural effects of diazepam on a rule-guided response selection task. *Neurosci Res*, 70(3):260–8, 2011.

[64] M. P. Paulus, J. S. Feinstein, G. Castillo, A. N. Simmons, and M. B. Stein. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. *Archives of General Psychiatry*, 62(3):282–288, 2005.

[65] M. Ragnehed, I. Håkansson, M. Nilsson, P. Lundberg, B. Söderfeldt, and M. Engström. Influence of diazepam on clinically designed fMRI. *The Journal of neuropsychiatry and clinical neurosciences*, 19(2):164–172, 2007.

[66] H. Jokeit, M. Okujava, and F. G. Woermann. Carbamazepine reduces memory induced activation of mesial temporal lobe structures: a pharmacological fMRI-study. *BMC Neurol*, 1:6, 2001.

[67] X. Li, C. H. Large, R. Ricci, J. J. Taylor, Z. Nahas, D. E. Bohning, P. Morgan, and M. S. George. Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal modeling to understand the discrete circuit specific changes of medications: lamotrigine and valproic acid changes in motor or prefrontal effective connectivity. *Psychiatry Res*, 194(2):141–8, 2011.

[68] X. Li, R. Ricci, C. H. Large, B. Anderson, Z. Nahas, D. E. Bohning, and M. S. George. Interleaved transcranial magnetic stimulation and fMRI suggests that lamotrigine and valproic acid

have different effects on corticolimbic activity. *Psychopharmacology (Berl)*, 209(3):233–44, 2010.

[69] E. C. Bell, M. C. Willson, A. H. Wilman, S. Dave, and P. H. Silverstone. Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. *Hum Psychopharmacol*, 20(6):415–24, 2005.

[70] R. L. Aupperle, L. Ravindran, D. Tankersley, T. Flagan, N. R. Stein, A. N. Simmons, M. B. Stein, and M. P. Paulus. Pregabalin influences insula and amygdala activation during anticipation of emotional images. *Neuropsychopharmacology*, 36(7):1466–77, 2011.

[71] E. A. Thomas and S. Petrou. Network-specific mechanisms may explain the paradoxical effects of carbamazepine and phenytoin. *Epilepsia*, 54(7):1195–202, 2013.

[72] Z. Haneef, H. S. Levin, and S. Chiang. Brain graph topology changes associated with anti-epileptic drug use. *Brain Connect*, 5(5):284–91, 2015.

[73] J. F. Jansen, A. P. Aldenkamp, H. J. Marian Majoie, R. P. Reijs, M. C. de Krom, P. A. Hofman, M. Eline Kooi, K. Nicolay, and W. H. Backes. Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. *Epilepsy Behav*, 9(1):181–5, 2006.

[74] A. De Ciantis, M. Muti, C. Piccolini, M. Principi, A. Di Renzo, R. De Ciantis, D. Frondizi, G. Iannone, P. Ottaviano, and M. Piccirilli. A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. *Neurol Sci*, 29 Suppl 1: S141–3, 2008.

[75] J. P. Szaflarski and J. B. Allendorfer. Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy. *Epilepsy Behav*, 24(1):74–80, 2012.

[76] C. L. Yasuda, M. Centeno, C. Vollmar, J. Stretton, M. Symms, F. Cendes, M. A. Mehta, P. Thompson, J. S. Duncan, and M. J. Koepp. The effect of topiramate on cognitive fMRI. *Epilepsy Res*, 105(1-2):250–5, 2013.

[77] B. Wandschneider, J. Stretton, M. Sidhu, M. Centeno, L. R. Kozák, M. Symms, P. J. Thompson, J. S. Duncan, and M. J. Koepp. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. *Neurology*, 83(17):1508–1512, 2014.

[78] B. P. Kay, M. W. DiFrancesco, M. D. Privitera, J. Gotman, S. K. Holland, and J. P. Szaflarski. Reduced default mode network connectivity in treatment-resistant idiopathic generalized epilepsy. *Epilepsia*, 54(3):461–70, 2013.

[79] N. W. Duncan, C. Wiebking, and G. Northoff. Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans – a review of multimodal imaging studies. *Neurosci Biobehav Rev*, 47C:36–52, 2014.

[80] C. J. Stagg, S. Bestmann, A. O. Constantinescu, L. M. Moreno, C. Allman, R. Mekle, M. Woolrich, J. Near, H. Johansen-Berg, and J. C. Rothwell. Relationship between physiological measures of excitability and levels of glutamate and GABA in the human motor cortex. *J Physiol*, 589(Pt 23): 5845–55, 2011.

[81] J. A. Detre, H. Rao, D. J. Wang, Y. F. Chen, and Z. Wang. Applications of arterial spin labeled MRI in the brain. *J Magn Reson Imaging*, 35(5):1026–37, 2012.

[82] P. Beleza. Refractory epilepsy: a clinically oriented review. *Eur Neurol*, 62(2):65–71, 2009.

[83] Z. J. Wang, C. Bergqvist, J. V. Hunter, D. Jin, D. J. Wang, S. Wehrli, and R. A. Zimmerman. In vivo measurement of brain metabolites using two-dimensional double-quantum MR spectroscopy–exploration of GABA levels in a ketogenic diet. *Magn Reson Med*, 49(4):615–9, 2003.

[84] J. W. Pan, R. B. Duckrow, J. Gerrard, C. Ong, L. J. Hirsch, Jr. Resor, S. R., Y. Zhang, O. Petroff, S. Spencer, H. P. Hetherington, and D. D. Spencer. 7T MR spectroscopic imaging in the localization of surgical epilepsy. *Epilepsia*, 54(9):1668–78, 2013.

[85] D. L. Rothman, H. M. De Feyter, R. A. de Graaf, G. F. Mason, and K. L. Behar. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. *NMR Biomed*, 24(8):943–57, 2011.

[86] E. A. van Vliet, W. M. Otte, J. A. Gorter, R. M. Dijkhuizen, and W. J. Wadman. Longitudinal assessment of blood-brain barrier leakage during epileptogenesis in rats. a quantitative MRI study. *Neurobiol Dis*, 63:74–84, 2014.

[87] M. P. van den Heuvel, C. J. Stam, R. S. Kahn, and H. E. Hulshoff Pol. Efficiency of functional brain networks and intellectual performance. *J Neurosci*, 29(23):7619–24, 2009.

Chapter 3

Glutamate concentrations vary with antiepileptic drug use and mental slowing

T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, R. H. C. Lazeron, N. A. J. Puts, R. A. E. Edden, P. A. M. Hofman, A. J. A. de Louw, W. H. Backes, J. F. A. Jansen, *Epilepsy&Behavior 2016; 64: 200–205*,
DOI: 10.1007/s10439-014-1198-y

Abstract

Objective: Although antiepileptic drugs (AEDs) are effective in suppressing epileptic seizures, they also induce (cognitive) side effects, with mental slowing as a general effect. This study aimed to assess whether concentrations of the MR detectable neurotransmitters glutamate and GABA are associated with mental slowing in patients with epilepsy taking AEDs.

Methods: Cross-sectional data were collected from 55 patients with localization-related epilepsy using a variety of AEDs from three risk categories, i.e. AEDs with low, intermediate, and high risks of developing cognitive problems. Patients underwent 3T MR spectroscopy, including a PRESS (n=55) and MEGA-PRESS (n=43) sequence, to estimate occipital glutamate and GABA concentrations, respectively. The association was calculated between neurotransmitter concentrations and central information processing speed, which was measured using the Computerized Visual Searching Task (CVST) and compared between the different risk categories.

Results: Combining all groups, patients with lower processing speeds had lower glutamate concentrations. Patients in the high-risk category had a lower glutamate concentration and lower processing speed compared with patients taking low-risk AEDs. Patients taking intermediate-risk AEDs also had a lower glutamate concentration compared with patients taking low-risk AEDs, but processing speed did not differ significantly between those groups. No associations were found between the GABA concentration and risk category or processing speed.

Conclusion: For the first time a relation is shown between glutamate concentration and both mental slowing and AED use. It is suggested that the reduced excitatory action, reflected by lowered glutamate concentrations, may have contributed to the slowing of information processing in patients using AEDs with higher risks of cognitive side effects.

Introduction

Although antiepileptic drugs (AEDs) are effective in suppressing epileptic seizures, they may also induce side effects. These side effects can strongly affect the quality of life of patients, with slowing of central information processing speed as the dominant cognitive effect of most AEDs and also the first sign of cognitive adverse effects [1, 2]. Cognitive side effects are commonly seen among the different AED regimes, but the occurrence and severity vary between different AEDs. The newer AEDs lamotrigine and levetiracetam are suggested to have no adverse, and maybe even beneficial cognitive effects, while topiramate is known for its deleterious cognitive effects. Other AEDs, such as valproate or carbamazepine, are associated with milder cognitive effects [1, 3, 4].

AEDs aim to control epileptic seizures via a number of distinct mechanisms of action, which can be subdivided in suppression of the excitatory mechanisms or enhancement of inhibitory mechanisms [5]. Although cognitive side effects are likely to result from the anticonvulsant activity of the AEDs, these effects cannot be linked to any particular mechanism of action, and other mechanisms might be involved as well [6]. It has been hypothesized that especially AEDs with mechanisms acting on the γ-aminobutyric acid (GABA) system cause cognitive side effects, but similar side effects are also induced by AEDs with other mechanisms of action [7]. Furthermore, it is currently not possible to predict which patients will suffer from these side effects and who will not. However, compliance to AED therapy relies on efficacy as well as tolerance to side effects.

In vivo measurements of the main inhibitory and excitatory neurotransmitters GABA and glutamate can be provided by proton magnetic resonance spectroscopy (^{1}H-MRS). In healthy individuals, higher GABA concentrations and lower glutamate concentrations have been associated with better cognitive performance [8–10]. Previous studies also showed that AED treatment can be associated with altered neurotransmitter concentrations [11]. Although several studies have been performed to associate GABA and glutamate concentrations with seizure control [12–14], to our knowledge the association with cognitive side effects has not been investigated yet. The aim of this cross-sectional study was to assess whether GABA and glutamate concentrations can be linked to cognitive functioning, in terms of decreased processing speed, in patients with epilepsy on long-term AED treatment.

Methods

Patients

Patients with localization-related epilepsy, recruited from our tertiary epilepsy referral center, were included in this study. Inclusion criteria were an age between 18 and 70 years and no contraindications for MRI (metal implants, claustrophobia, or pregnancy). This study was approved by the local Medical Ethical Committee and written informed consent was obtained from all patients before the examination.

To obtain a variation in information processing speed, three groups of patients using different AEDs were included. The groups were defined according to Samarasekera et al. [15], based on the known risk of developing cognitive side effects: a low-risk category (levetiracetam and lamotrigine), an intermediate-risk category (valproate, carbamazepine, oxcarbazepine and phenytoin), and a high-risk category (topiramate). Both patients on mono- and polytherapy were included, but patients took maximal two different AEDs. Patients on polytherapy were classified according to the AED in the highest risk category.

Neuropsychological investigation

Information processing speed was used as a measure for cognitive side effects, as slowing of central information processing speed is the most common side effect of AEDs [2]. For this, the Computerized Visual Searching Task (CVST) was used [16]. In this task, a centered grid pattern has to be compared with 24 surrounding grid patterns. Participants have to find the grid pattern identical to the centered pattern. The score is the average time needed to complete this task. Additionally, as global cognitive abilities are assumed to be unaffected by AEDs [2], the Raven Standard Progressive Matrices was performed to correct for possible variation in cognitive abilities between the patients [17]. This is a non-verbal reasoning test, in which participants have to identify the figure that is required to fulfill a series of eight other figures.

Data acquisition

MR data were acquired on a 3.0T MR scanner equipped with an 8-channel head coil (Philips Achieva, Philips Medical Systems, Best, the Netherlands). Glutamate concentrations were measured using a PRESS sequence (TE/TR: 35/2000 ms, 128 averages, VAPOR water suppression). GABA-edited MR spectra were acquired using a MEGA-PRESS sequence (TE/TR 68/2000 ms, 320 averages, with editing pulses at 1.9 (ON) and 7.46 ppm (OFF) interleaved in 40 blocks, MOIST water



Figure 3.1. Example of the voxel placement (A), a PRESS spectrum with the LCModel fit (in red), which fits a linear combination of metabolite spectra (B), and a MEGA-PRESS spectrum with the GANNET fit (in red), which only fits the GABA+ peak (GABA + co-edited macromolecules) (C). Individual glutamate or GABA fits are displayed in the figures as well.

suppression). Both spectra were acquired from the same 3x3x3 cm^3 voxel located around the parieto-occipital sulcus (Figure 3.1). This location has an optimal signal-to-noise ratio and is commonly selected in MRS studies [18]. To estimate the water signal, separate scans without water suppression were made directly after the PRESS and MEGA-PRESS scans (with TE/TR 35/2000 ms and 128 averages or TE/TR 68/2000 ms and 8 averages, respectively). Additionally, a T1-weighted scan was made to determine the voxel composition (voxel size 1x1x1 mm^3, flip angle 8°, 3D fast spoiled gradient echo sequence, TE/TI/TR 4.8/1022/8.3 ms, 180 slices).

Data analysis

PRESS spectra were analyzed using LCModel (version 6.3-1L). LCModel fits the spectrum with a linear combination of individual metabolite spectra [19]. A standard basis set with sixteen different simulated metabolite spectra was used in this analysis and spectra were analyzed within the resonance frequency range from 0.2 to 4.0 ppm. In addition to glutamate, tNAA (N-acetyl aspartate + N-acetylaspartylglutamate), tCho (phosphorylcholine + glycerophosphorylcholine), and tCr (creatine + phosphocreatine) concentration estimates were collected for further analyses.

Gannet (version 2.0) was used for the preprocessing and quantification of the GABA+ concentration (i.e. GABA and co-edited macromolecules) [20]. The GABA peak is fitted to a Gaussian model curve. Gannet is designed for GABA+ quantification but also enables Glx quantification from MEGA-PRESS spectra [21]. Gannet has the advantage that it also includes frequency and phase corrections [22,

23]. MEGA-PRESS scans are more vulnerable for field drifts and movement artifacts than typical PRESS scans because of the addition of an editing pulse and subtraction of ON and OFF scans to obtain difference spectra, potentially leading to subtraction artifacts. Frequency correction can reduce quantification errors [22]. All spectra were visually inspected on subtraction artifacts and adequate noise levels.

Repeatability of these methods was tested in five healthy volunteers (age 29±4 year, four male), who underwent two PRESS and MEGA-PRESS scans immediately after each other. The results showed a coefficient of variation of 2.9%, 5.2% and 8.1% for glutamate (using PRESS/LCModel), Glx (using MEGA-PRESS/Gannet) and GABA+, respectively. Because of the better coefficient of variation of glutamate estimations with PRESS than Glx estimations with MEGA-PRESS, and because of a moderate concordance between these measurements in the included patients (Pearson correlation coefficient=0.31, p=0.046), only glutamate measurements with PRESS were considered in this study.

All concentrations are reported relative to the unsuppressed water signal from the same volume. FMRIB's Automated Segmentation Tool (FAST), part of FSL (version 5.0.1), was applied to determine the voxel composition in terms of gray matter, white matter, and cerebral spinal fluid (CSF) content [24, 25]. Assuming that the neurometabolites are only present in the gray and white matter, the concentrations relative to the water signal were corrected for the CSF content of the voxel. Therefore, the neurometabolite concentrations were divided by the sum of the gray and white matter fractions.

Statistical analysis

Associations between the neurometabolite concentrations (i.e. glutamate, GABA+, tNAA, tCho, and tCr) and CVST were tested with linear regression analysis, with CVST as dependent variable and the concentrations as independent variables. Separate analyses were performed for each neurometabolite. Besides the neurometabolite concentration, age and the percentage correct answers in the Raven test (as a measure for intelligence) were added to these analyses as independent variables, as the information processing speed usually correlates with age and cognitive abilities.

To test whether the neurometabolite concentrations varied with risk degree an ANCOVA (analysis of covariance) test was applied, with the neurometabolite concentrations as outcome variable and the risk categories as fixed factors. Covariates in the analyses were age, gender, and the gray matter fraction in the voxel (gray matter fraction divided by the sum of the white and gray matter fractions). In

case of significant group effects, post hoc tests (Students t-tests) were applied to test for individual group differences.

To check for possible confounding effects, the analyses were repeated with drug load (defined as the ratio of the prescribed daily dose to the defined daily dose [26]), having symptomatic epilepsy or epilepsy severity added as additional covariate. Epilepsy severity was defined by a composed score ranging from 0 to 7 based on seizure type (tonic-clonic:1, other:0), previous occurrence of status epilepticus (yes:1, no:0), seizure-related injury (yes:1, no:0), and seizure frequency (seizure free:0, yearly:1, monthly:2, weekly:3, daily:4). In all analyses, p-values<0.05 were considered significant.

Results

Patient characteristics

Fifty-eight patients were included in this study. Three of these patients did not finish the MRI examination because of claustrophobia, resulting in suitable data of 55 patients for further analysis. Seventeen of the 55 patients had symptomatic epilepsy. MRI lesions included cerebral atrophy (6), cortical dysplasias (5), infarctions (3), malformations (1), tumors (1), and cysts (1). The remaining 38 patients had non-symptomatic epilepsy.

The low- and intermediate-risk groups differed significantly in age and drug load (Table 3.1). Also the number of patients taking polytherapy was significantly higher in the intermediate- and high-risk categories than in the low-risk category. Patients in the different risk categories did not differ significantly in educational level, seizure frequency, epilepsy severity score, or years since epilepsy onset.

The CVST reaction time ranged from 7.3 to 30.8 s (mean±sd in a healthy adult population: 10.3±4.1 s [28]). Both the patients taking intermediate-risk and high-risk AEDs had a significantly lower processing speed compared with patients taking low-risk AEDs (p=0.003 and p=0.042, respectively, Table 3.1). When age, gender, and the percentage correct answers in the Raven test were added as covariates to this analysis (ANCOVA), there was a significant effect of risk category (p=0.009). Post hoc tests revealed a significantly longer CVST reaction time in the intermediate- (p=0.035, adjusted mean difference: 3.5 s), and in the high-risk categories (p=0.004, adjusted mean difference: 7.8 s), compared with patients taking low-risk AEDs. The CVST reaction time did not differ significantly between the intermediate- and high-risk groups. All participants had a Raven score above the 5th percentile of a healthy, age-matched adult population, and the Raven score was not significantly different between the groups.

Table 3.1. Patient characteristics for the three risk categories[a]. Results are displayed for the participants included in the PRESS analysis.

	Low-risk (n=16)	Intermediate-risk (n=34)	High-risk (n=5)
General			
Male/female	5/11 (31/69%)	16/18 (47/53%)	0/5
Age (years)[b]	39.5±13.4	50.7±12.5*	42.4±15.8
Educational level[c]	5 (range 2-6)	5 (range 2-7)	5 (range 4-6)
Epilepsy-related			
Symptomatic/non-symptomatic epilepsy	2/14 (13/88%)	15/19 (44/56%)	0/5
Seizure frequency			
Weekly	0	1 (3%)	0
Monthly	4 (25%)	3 (9%)	0
Yearly	2 (13%)	6 (18%)	2 (40%)
Seizure free	10 (63%)	24 (71%)	3 (60%)
Years since epilepsy onset[b]	22.7±11.7	30.4±13.4	26.8±23.3
Epilepsy severite score[b]	1.4±0.8	1.2±1.0	1.0±0.7
AED-related			
Mono-/polytherapy	16/0	8/26 (24/77%)*	3/2 (60/40%)†
Medication type			
CBZ	0	17 (50%)	1 (20%)
LEV	7 (44%)	6 (18%)	0
LTG	9 (56%)	10 (29%)	1 (20%)
OXC	0	4 (12%)	0
PHT	0	16 (47%)	0
TPM	0	0	5 (100%)
VPA	0	7 (21%)	1 (20%)
Drug load[b,d]	1.3±0.6	1.8±0.7*	1.2±1.0
Neuropsychological results			
CVST reaction time[b]	11.5±2.9	15.7±6.4*	20.2±6.7†
Raven (% correct answers)[b]	71.7±10.3%	73.2±10.1%	71.7±3.1%

Differences between the risk groups were tested using a Fisher's exact test (gender, symptomatic epilepsy, mono/polytherapy), a Mann-Whitney test (educational level, seizure frequency, epilepsy severity score), or a student's t-test (all remaining variables). *indicates significant differences between the low- and intermediate-risk category ($p<0.05$); †indicates differences between the low- and high-risk categories ($p<0.05$).

[a]Low-risk: lamotrigine (LTG), levetiracetam (LEV); Intermediate-risk: valproate (VPA), carbamazepine (CBZ), oxcarbazepine (OXC) and phenytoin (PHT); High-risk: topiramate (TPM)

[b]mean ± standard deviation

[c]Median (range). Scores are according to Verhage [27], range 1 (did not finish primary school) to 7 (Master's degree)

[d]The drug load is defined as the ratio of the prescribed daily dose to the defined daily dose [28]

Spectroscopy results

The quality of the PRESS spectra was adequate in all patients. Visual inspection did not reveal spectra of insufficient quality, all spectra had a signal-to-noise ratio above 20, and the Cramė r-Rao lower bounds (CRLB) of glutamate were below 10%. Forty-three MEGA-PRESS spectra were included in the statistical analysis (15 from the low-risk group, 26 from the intermediate-risk group, and 2 from the high-risk group). In four patients, no MEGA-PRESS data were available because of acquisition problems, and another eight MEGA-PRESS scans were excluded because of insufficient quality of the spectrum. The error of the GABA fit was below 15% in the remaining spectra, while the mean absolute drift of the water peak between two subsequent blocks was 0.009±0.004 ppm.

Across all participants, the glutamate and GABA concentrations were 9.3±0.8 i.u. (institutional units) and 1.7±0.4 i.u., respectively (mean±sd). tNAA, tCr, and tCho concentrations were 9.0±0.5 i.u., 6.8±0.6 i.u., and 1.2±0.2 i.u., respectively.

The CVST reaction time was significantly associated with glutamate concentration (β=-3.1, p=0.001, with correction for age and global intelligence), indicating that patients with a lower processing speed had a lower glutamate concentration (Figure 3.2). The CVST reaction time was not significantly associated with the GABA (p=0.45), tNAA (p=0.99), tCr (p=0.82), or tCho (p=0.13) concentrations.

The glutamate and GABA concentrations are illustrated for the different groups in Figure 3.3. A significant effect of cognitive risk category on the glutamate concentration was observed (p=0.028, ANCOVA, with age, gender, and gray matter fraction as covariates). Post hoc tests showed a significantly lower glutamate concentration in the intermediate-risk category than in the low-risk category (p=0.021, adjusted mean difference 0.49) and in the high- compared with the low-risk category (p=0.032, adjusted mean difference 0.72). The intermediate- and high-risk categories did not differ significantly in the glutamate concentrations (p=0.47). Risk category did not have a significant effect on the GABA (p=0.83), tNAA (p=0.47), tCho (p=0.085), or tCr (p=0.17) concentration.

The additional analyses, with epilepsy severity score, drug load, or having symptomatic epilepsy added as covariates, showed comparable results as the analyses without these additional covariates (<10% change in effect size). Furthermore, epilepsy severity, drug load, or having symptomatic epilepsy was not a significant covariate in any of the analyses.



Figure 3.2. Association of the glutamate concentration and CVST reaction time. Patients with lower glutamate concentrations, had a longer CVST reaction time, i.e. a lower processing speed, than patients with higher glutamate concentrations. The depicted line represents the uncorrected linear regression estimate to guide the eye. This association remained significant after correction for age and global intelligence (β=-3.1, p=0.001). It can be noticed that patients taking low-risk AEDs (open circles), had high glutamate concentrations and low-CVST reaction times, while lower glutamate concentrations and higher CVST reaction times were only measured in patients taking intermediate- (gray circles) or high-risk (black circles) AEDs. CVST: computerized visual searching task

Discussion

This study assessed associations between neurotransmitter concentrations, AED treatment, and cognitive functioning in patients with epilepsy. Lower glutamate concentrations were associated with a lower processing speed, the most common type of drug-induced cognitive impairment. Furthermore, patients taking AEDs from higher-risk categories had lower glutamate concentrations than patients taking AEDs from lower-risk categories. No significant associations were found between the GABA+ concentration and risk category or processing speed.

Glutamate concentrations and cognitive slowing

To our knowledge, this is the first study showing associations between neurotransmitter concentrations and drug-induced cognitive side effects (i.e. mental slowing) in patients with epilepsy. Studies in other diseases did also show associations between the glutamate concentration and cognitive functioning, but the variety of the



Figure 3.3. Glutamate (A) and GABA (B) concentrations for the three risk groups. Concentrations are relative to the water concentration, corrected for the cerebral spinal fluid content of the voxel, and displayed in institutional units. Low-risk category: lamotrigine or levetiracetam; Intermediate-risk category: carbamazepine, oxcarbazepine, phenytoin or valproate; High-risk category: topiramate. Standard deviations are displayed with error bars. *indicate significant differences ($p<0.05$), when adjusted for age, gender, and gray matter fraction.

applied cognitive tests is large, and both positive and negative associations have been found [29]. Different explanations are proposed for these associations. For instance, it is hypothesized that neurotoxic effects of high glutamate concentrations affect cognitive functioning [30], that a higher GABA/glutamate concentration improves decision-making [8], or that glutamate concentration acts as a marker for neuronal integrity [31]. Precise associations between glutamate and cognitive function and the underlying mechanisms may depend on the specific disease and cognitive functions being studied.

The glutamate concentration measured by MRS is a combination of glutamate functioning as neurotransmitter and glutamate stored in synaptic vesicles and metabolic pools. Although the precise mechanisms are unknown, the glutamate concentration appears to be roughly linearly related to excitatory activity, possibly because of its involvement in the glucose metabolism in the brain [32, 33]. As AEDs generally tend to suppress (abnormal) brain activity [5], it seems likely that the lower glutamate concentrations in this study reflect more suppressed brain activity, which may be associated with a slowing of information processing at the downside of this effect.

AED use and glutamate concentrations

Although differences in glutamate concentrations were observed between the different risk categories, none of the known mechanisms of action of AEDs are likely to affect the glutamate concentration directly [5]. However, it is possible that modulation of the sodium channels, seen in PHT, CBZ, OXC, TPM, and VPA, which blocks high-frequency repetitive action potentials, indirectly decreases the glutamate release. Three previous longitudinal studies showed no changes in the Glx concentration (glutamate and its precursor glutamine combined) after VPA use, or glutamate concentrations after TPM or LEV use [34–36], AEDs which were also used in the current study. Taken together, the current study does not provide evidence that AEDs from different risk categories alter glutamate concentrations directly, but the results do suggest a link between glutamate concentration and mental slowing due to AED use.

GABA

In this study, no associations were found between the GABA concentration and information processing speed or cognitive risk category, in contrast to the hypothesized involvement of GABAergic mechanisms in cognitive side effects of AEDs [7, 37]. Existing associations might have been undetected in this study because of the small group size. Because of exclusion of MEGA-PRESS spectra, this group size was smaller compared with the other results (n=43 versus n=55). Also confounding effects of the different AEDs might have had different effects on the GABA concentration. For instance, both TPM and LTG are suggested to increase the GABA concentration, but a higher increase was reported with TPM use than with LTG use [38]. Using the current clinical study design, it is not feasible to assess distinct effects of the different AEDs, because of the many different combinations of AEDs which were being used by the included patients. However, it cannot be excluded that for individual AEDs, also GABA concentrations are associated with cognitive functioning.

Other neurometabolites

tNaa, tCho, and tCr concentrations were not significantly associated with CVST reaction time nor risk group in this study, while previous studies did show associations with for example NAA and information processing speed [39] or executive functioning [40] in healthy elderly populations. Age-specific mechanisms may underlie these associations, which cannot be generalized to other study populations. For instance, NAA is considered a marker for neuronal integrity and is often asso-

ciated with cognitive functioning. However, cognitive side effects of AED use are reversible and, therefore, not likely to be accompanied by neuronal cell damage as might be the case in aging. Previous studies have not reported associations with tNAA, tCho, or tCr and AED use [11].

Study considerations

This study was performed in patients with epilepsy on long-term AED treatment, which is most relevant for clinical practice. However, inherent to these studies is the heterogeneity of the study population and the different combinations of AEDs that were taken. An important possible confounder in this study is whether patients were on mono- or polytherapy, which largely coincides with taking AEDs from the low- or intermediate-risk category. Importantly, polytherapy itself is already associated with a higher risk of cognitive side effects [41]. It can furthermore not be excluded that both glutamate concentrations and processing speed were affected by epilepsy characteristics or underlying causes rather than AED use. Future studies are needed to distinguish these factors, and to clarify the precise, causal relationship between neurotransmitter concentrations, AED use, and cognitive side effects.

Because of its negative cognitive side effects, topiramate is not commonly prescribed in our epilepsy center. This resulted in a limited number of patients taking high-risk AEDs in this study, but the results of this group are in line with the results from the intermediate-risk category. The lack of significant differences between the intermediate- and high-risk categories might therefore be due to the small group size of the high-risk category.

The MRS measurements used in this study showed good repeatability. However , the low-concordance between glutamate estimations from PRESS and Glx from MEGA-PRESS is striking. A possible explanation is the presence of macromolecules in one of these spectra, but future studies are prompted to investigate this topic. A final consideration regarding MRS measurements is the voxel location. As in many previous studies, the occipital lobe was chosen because it gives the best signal-to-noise ratio [18, 22]. However, regions important for cognitive processes include the prefrontal cortex and subcortical structures, and not the occipital lobe [42]. Currently, it remains to be determined whether relevant spatial variations exist in the neurotransmitter concentrations in relation to adverse cognitive effects.

Future perspectives

Currently, it is not possible to predict which patients will or will not suffer from these side effects, though this would aid clinical decision making. The results of this study show the potential of glutamate measurements as a candidate biomarker. In order to predict these side effects, it is necessary to first longitudinally assess changes in neurotransmitter concentration, to see whether the differences in glutamate levels possibly precede the cognitive problems or coincide with the cognitive problems.

Conclusion

For the first time a relation is shown between lowered glutamate concentrations and both AED use and mental slowing in patients with epilepsy. This observation hints at a possible contribution to a neurobiological mechanism of mental slowing due to AED use. More knowledge about this relation might help to explain why some patients with epilepsy experience cognitive side effects while the cognitive function of other patients is not affected by AEDs. Future studies with MRS and AEDs are warranted to further elucidate more details of underlying mechanisms.

Acknowledgements

The authors thank R. Berting for his assistance with the image acquisition and M. Geerlings and J. Slenter for continuous hardware and software support.

References

[1] D. M. IJff and A. P. Aldenkamp. Cognitive side-effects of antiepileptic drugs. *Handb Clin Neurol.*, 111:707–718, 2013.

[2] E. Grevers, L. E. Breuer, I. Jff DM, and A. P. Aldenkamp. Mental slowing in relation to epilepsy and antiepileptic medication. *Acta Neurol Scand*, 2015.

[3] C. Luoni, F. Bisulli, M. P. Canevini, G. De Sarro, C. Fattore, C. A. Galimberti, G. Gatti, A. La Neve, G. Muscas, L. M. Specchio, S. Striano, E. Perucca, and Sophie Study Group. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. *Epilepsia*, 52 (12):2181–91, 2011.

[4] R. S. Fisher, B. G. Vickrey, P. Gibson, B. Hermann, P. Penovich, A. Scherer, and S. Walker. The impact of epilepsy from the patient's perspective II: views about therapy and health care. *Epilepsy Research*, 41(1):53–62, 2000.

[5] M. A. Rogawski and W. Loscher. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci*, 5 (7):553–64, 2004.

[6] S. A. Hamed. The aspects and mechanisms of cognitive alterations in epilepsy: the role of antiepileptic medications. *CNS Neurosci Ther*, 15(2):134–56, 2009.

[7] R. Sankar and G. L. Holmes. Mechanisms of action for the commonly used antiepileptic drugs: Relevance to antiepileptic drug–associated neurobehavioral adverse effects. *Journal of Child Neurology*, 19(1 suppl):S6–S14, 2004.

[8] G. Jocham, L. T. Hunt, J. Near, and T. E. Behrens. A mechanism for value-guided choice based on the excitation-inhibition balance in prefrontal cortex. *Nat Neurosci*, 15(7):960–1, 2012.

[9] K. Sandberg, J. U. Blicher, M. Y. Dong, G. Rees, J. Near, and R. Kanai. Occipital GABA correlates with cognitive failures in daily life. *Neuroimage*, 87:55–60, 2014.

[10] P. Sumner, R. A. Edden, A. Bompas, C. J. Evans, and K. D. Singh. More GABA, less distraction: a neurochemical predictor of motor decision speed. *Nat Neurosci*, 13(7):825–7, 2010.

[11] T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, P. A. Hofman, M. C. Vlooswijk, R. P. Rouhl, A. J. de Louw, W. H. Backes, and J. F. Jansen. Metabolic and functional MR biomarkers of antiepileptic drug effectiveness: A review. *Neurosci Biobehav Rev*, 59:92–9, 2015.

[12] S. G. Mueller, O. M. Weber, C. O. Duc, B. Weber, D. Meier, W. Russ, P. Boesiger, and H. G. Wieser. Effects of vigabatrin on brain GABA+/Cr signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: Responder characteristics. *Epilepsia*, 42(1):29–40, 2001.

[13] S. G. Mueller, O. M. Weber, C. O. Duc, D. Meier, W. Russ, P. Boesiger, and H. G. Wieser. Effects of vigabatrin on brain GABA+/Cr signals in focus distant and focus near brain regions monitored by 1H-NMR spectroscopy. *European Journal of Neurology*, 10(1):45–52, 2003.

[14] O. A. C. Petroff, K. L. Behar, R. H. Mattson, and D. L. Rothman. Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. *Journal of neurochemistry*, 67(6):2399–2404, 1996.

[15] S. R. Samarasekera, C. Helmstaedter, and M. Reuber. Cognitive impairment in adults with epilepsy: The relationship between subjective and objective assessments of cognition. *Epilepsy Behav*, 52(Pt A):9–13, 2015.

[16] A. P. Aldenkamp, J. Arends, N. M. de la Parra, and E. J. W. Migchelbrink. The cognitive impact of epileptiform EEG discharges and short epileptic seizures: relationship to characteristics of the cognitive tasks. *Epilepsy & Behavior*, 17(2):205–209, 2010.

[17] J. Raven, J. C. Raven, and J. H. Court. Manual for Raven's Progressive Matrices and Vocabulary Scales. Section 3: The Standard Progressive Matrices. *San Antonio, TX: Harcourt Assessment*, 2000.

[18] N. A. Puts and R. A. Edden. In vivo magnetic resonance spectroscopy of GABA: a methodological review. *Prog Nucl Magn Reson Spectrosc*, 60:29–41, 2012.

[19] S. W. Provencher. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magnetic Resonance in Medicine*, 30(6):672–679, 1993.

[20] R. A. Edden, N. A. Puts, A. D. Harris, P. B. Barker, and C. J. Evans. Gannet: A batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra. *J Magn Reson Imaging*, 40(6):1445–52, 2014.

[21] R. L. O'Gorman, L. Michels, R. A. Edden, J. B. Murdoch, and E. Martin. In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects. *J Magn Reson Imaging*, 33(5):1262–7, 2011.

[22] C. J. Evans, N. A. Puts, S. E. Robson, F. Boy, D. J. McGonigle, P. Sumner, K. D. Singh, and R. A. Edden. Subtraction artifacts and frequency (mis-)alignment in J-difference GABA editing. *J Magn Reson Imaging*, 38(4):970–5, 2013.

[23] J. Near, R. Edden, C. J. Evans, R. Paquin, A. Harris, and P. Jezzard. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. *Magn Reson Med*, 73(1):44–50, 2015.

[24] Y. Zhang, M. Brady, and S. Smith. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. *Medical Imaging, IEEE Transactions on*, 20(1):45–57, 2001.

[25] S. M. Smith, M. Jenkinson, M. W. Woolrich, C. F. Beckmann, T. E. Behrens, H. Johansen-Berg, P. R. Bannister, M. De Luca, I. Drobnjak, D. E. Flitney, R. K. Niazy, J. Saunders, J. Vickers, Y. Zhang, N. De Stefano, J. M. Brady, and P. M. Matthews. Advances in functional and structural

MR image analysis and implementation as FSL. *NeuroImage*, 23 Suppl 1:S208–19, 2004.

[26] M. W. Lammers, Y. A. Hekster, A. Keyser, H. Meinardi, W. O. Renier, and H. van Lier. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. *Epilepsia*, 36(5):440–446, 1995.

[27] F. Verhage. *Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar*. Van Gorcum Assen, 1964.

[28] W. Alpherts and A. P. Aldenkamp. FePsy: the iron psyche. *Heemstede: Instituut voor Epilepsiebestrijding*, 1994.

[29] G. Ende. Proton magnetic resonance spectroscopy: Relevance of glutamate and GABA to neuropsychology. *Neuropsychol Rev*, 25(3):315–25, 2015.

[30] I. K. Lyoo, S. J. Yoon, G. Musen, D. C. Simonson, K. Weinger, N. Bolo, C. M. Ryan, J. E. Kim, P. F. Renshaw, and A. M. Jacobson. Altered prefrontal glutamate–glutamine–γ-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus. *Archives of general psychiatry*, 66(8):878–887, 2009.

[31] P. G. Unschuld, R. A. Edden, A. Carass, X. Liu, M. Shanahan, X. Wang, K. Oishi, J. Brandt, S. S. Bassett, G. W. Redgrave, R. L. Margolis, P. C. van Zijl, P. B. Barker, and C. A. Ross. Brain metabolite alterations and cognitive dysfunction in early huntington's disease. *Mov Disord*, 27(7): 895–902, 2012.

[32] C. D. Rae. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. *Neurochem Res*, 39(1):1–36, 2014.

[33] Jr. Novotny, E. J., R. K. Fulbright, P. L. Pearl, K. M. Gibson, and D. L. Rothman. Magnetic resonance spectroscopy of neurotransmitters in human brain. *Ann Neurol*, 54 Suppl 6:S25–31, 2003.

[34] R. J. Simister, M. A. McLean, G. J. Barker, and J. S. Duncan. The effect of sodium valproate on proton MRS visible neurochemical concentrations. *Epilepsy Res*, 74(2-3):215–9, 2007.

[35] C. M. Moore, M. Wardrop, B. Frederick B. de, and P. F. Renshaw. Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0T magnetic resonance spectroscopy study. *Psychopharmacology (Berl)*, 188(2):236–43, 2006.

[36] M. H. Pollack, J. E. Jensen, N. M. Simon, R. E. Kaufman, and P. F. Renshaw. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. *Prog Neuropsychopharmacol Biol Psychiatry*, 32(3):739–43, 2008.

[37] M. Mula and M. R. Trimble. Antiepileptic drug-induced cognitive adverse effects. *CNS drugs*, 23 (2):121–137, 2009.

[38] R. Kuzniecky, S. Ho, J. Pan, R. Martin, F. Gilliam, E. Faught, and H. Hetherington. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. *Neurology*, 58 (3):368–372, 2002.

[39] P. Kochunov, T. Coyle, J. Lancaster, D. A. Robin, J. Hardies, V. Kochunov, G. Bartzokis, J. Stanley, D. Royall, A. E. Schlosser, et al. Processing speed is correlated with cerebral health markers in the frontal lobes as quantified by neuroimaging. *NeuroImage*, 49(2):1190–1199, 2010.

[40] R. A. Charlton, D. J. O. McIntyre, F. A. Howe, R. G. Morris, and H. S. Markus. The relationship between white matter brain metabolites and cognition in normal aging: the GENIE study. *Brain research*, 1164:108–116, 2007.

[41] P. Kwan and M. J. Brodie. Neuropsychological effects of epilepsy and antiepileptic drugs. *The Lancet*, 357(9251):216–222, 2001.

[42] R. Cabeza and L. Nyberg. Imaging cognition II: An empirical review of 275 PET and fMRI studies. *Journal of cognitive neuroscience*, 12(1):1–47, 2000.

Chapter 4

Chronic antiepileptic drug use and functional network efficiency

T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, R. H. C. Lazeron, P. A. M. Hofman, A. J. A. de Louw, W. H. Backes, J. F. A. Jansen,
World Journal of Radiology (In press)

Abstract

Objective: To increase our insight in the neuronal mechanisms underlying cognitive side effects of antiepileptic drug (AED) treatment.

Methods: The relation between functional MR-acquired brain network measures, AED use, and cognitive function was investigated. Three groups of patients with epilepsy with a different risk profile for developing cognitive side effects were included: a 'low-risk' category (lamotrigine or levetiracetam, n=16), an 'intermediate-risk' category (carbamazepine, oxcarbazepine, phenytoin, or valproate, n=34) and a 'high-risk' category (topiramate, n=5). Brain connectivity was assessed using resting state functional MRI and graph theoretical network analysis. The Computerized Visual Searching Task was used to measure central information processing speed, a common cognitive side effect of AED treatment.

Results: Central information processing speed was lower in patients taking AEDs from the intermediate- and high-risk categories, compared with patients from the low-risk category. The effect of risk category on global efficiency was significant ($p<0.05$, ANCOVA), with a significantly higher global efficiency for patient from the low-risk category compared with the high-risk category ($p<0.05$, post hoc test). Risk category had no significant effect on the clustering coefficient (ANCOVA, $p>0.2$). Also no significant associations between information processing speed and global efficiency or the clustering coefficient (linear regression analysis, $p>0.15$) were observed.

Conclusion: Only the four patients taking topiramate show aberrant network measures, suggesting that alterations in functional brain network organization may be only subtle and measureable in patients with more severe cognitive side effects.

Introduction

Epilepsy is generally treated with antiepileptic drugs (AEDs). A persistent problem in AED treatment is the occurrence of adverse events among which cognitive side effects are commonly seen [1, 2]. The cognitive side effects account for a high percentage of the disease burden [3] and lead to early drug discontinuation [4]. The prevalence and severity of the cognitive side effects varies among different AEDs. Several AEDs, such as topiramate, are associated with cognitive problems such as language deficit (anomia), while other AEDs such as lamotrigine seem to induce less cognitive side effects or even have activating effects [5]. Despite specific differences, a decreased central information processing speed is commonly observed among the different AEDs to some extent [2].

AEDs control epileptic seizures via several distinct mechanisms, such as enhancement of GABAergic inhibition, reduction of glutamatergic neurotransmission, or modulation of the voltage-gated ion channels [6]. Changes in brain metabolic processes also affect healthy brain activity, and are likely to be responsible for cognitive side effects [1]. Functional magnetic resonance imaging (fMRI) enables assessment of this brain activity, and can be employed to measure combined effects of different mechanism of action of AEDs [7]. Several fMRI studies have shown altered brain activity patterns in healthy participants [8] or patients with epilepsy [9, 10] treated with AEDs. For instance, altered brain activity patterns appeared to be associated with language impairments when taking topiramate [11–13].

Cognitive functions are mediated by the concerted action of multiple and distributed brain regions. These brain regions show correlations of their fMRI time signals, which is commonly interpreted as functional connectivity. Collectively, these functional connections form a brain network, which can be analyzed and characterized using graph theoretical analysis. Brain networks appear to be efficient networks, characterized by a high functional segregation and integration, i.e. different brain regions form densely interconnected groups, enabling specialized information processing, and also rapid communication between distributed brain regions. Several graph measures are available to quantify these characteristics [14].

Cognitive performance has been associated with the efficiency of functional brain networks [15, 16], while impaired functional brain networks have been associated with cognitive decline in epilepsy [17, 18]. Furthermore, associations between drug load, cognition and graph measures were shown in one of these studies, although this was not the main focus of the current study [17]. Another study associated the use of carbamazepine with altered graph measures when compared with other AEDs, but did not investigate the relation with cognitive effects [19]. In

the current study, we aim to test whether chronic use of AEDs, associated with a high risk for cognitive side effects, affects functional resting-state network measures differently than long-term use of AEDs associated with milder cognitive side effects. Furthermore, we will test whether functional resting-state network measures are associated with impaired cognitive functioning.

Methods

Patients

Three groups of patients with epilepsy were compared in this observational, cross-sectional study [20]. These groups were subdivided based on the AEDs that were being used, in accordance to Samarasekera et al. [21]. The first group, the low-risk category, consisted of patients using lamotrigine or levetiracetam. Patients taking carbamazepine, oxcarbazepine, phenytoin, or valproate were included in the intermediate-risk category, while the high-risk category comprised patients taking topiramate. Patients on polytherapy took at most two different AEDs and were categorized according to their AED associated with the greatest cognitive risk. By including patients with AEDs from the three risk groups, a range in slowing of information processing speed is set out for.

All patients were clinically diagnosed with localization-related epilepsy and aged between 18 and 70 years. The patients were recruited from our tertiary epilepsy referral center. Participants not eligible for MRI, because of metal implants, claustrophobia, or pregnancy, were excluded from this study. Furthermore, patients did not experience seizures at least 12 hours prior to MRI. This study was approved by the local Medical Ethical Committee and all participants provided written informed consent.

Neuropsychological investigation

Cognitive functioning was assessed by two neuropsychological tasks. The Computerized Visual Searching Task (CVST) was used to measure visual (complex) information processing speed [22]. Slowing of this central information processing speed is a common side effect of AEDs [2], and therefore the CVST is considered to be sensitive for treatment effects [23]. With the CVST, a centered grid is shown surrounded by 24 other grid patterns. Participants have to find the (only) grid identical to the centered one as fast as possible.

The Raven Standard Progressive Matrices was administered to assess global cognitive performance. This is a non-verbal reasoning test which gives an indication

of fluid intelligence [24]. Previous studies suggested that intelligence stays relatively unaffected by AEDs [25].

Epilepsy severity

As several epilepsy related characteristics might affect functional brain networks [26], a score was composed to account for these effects. This epilepsy severity score was assessed in all patients and compared between the different risk categories. Epilepsy severity was characterized using a summarized score between zero and seven, composed by the sum of subscores for seizure type (tonic-clonic: 1, other: 0), previous occurrence of status epilepticus (yes: 1, no: 0), seizure-related injury (yes: 1, no: 0) and seizure frequency (seizure free: 0, yearly: 1, monthly: 2, weekly: 3, daily: 4).

MRI data acquisition

MRI data were acquired on a 3.0T MRI scanner equipped with an 8-channel head coil (Philips Achieva, Philips Medical Systems, Best, the Netherlands). The scanning protocol included resting-state functional MRI and a T1-weighted scan. Functional MRI data were acquired using whole-brain single-shot multi-slice echo planar imaging (EPI) sequence sensitive to the blood-oxygen-level-dependent (BOLD) effect (195 volumes, 32 slices, in-plane resolution 2x2 mm^2, 4 mm thick slices, repetition time 2000 ms, echo time 35 ms, flip angle: 90°, acquisition time: 7 min). A 3D T1-weighted scan was acquired for anatomic reference (voxel size 1x1x1 mm^3, repetition time 8.3 ms, echo time 4.8 ms, inversion time 1022 ms, 180 slices, flip angle 8°, acquisition time 6 min).

Data preprocessing

Preprocessing of the functional images was performed using SPM8 (Wellcome Department of Cognitive Neurology, London, UK). The functional images were corrected for differences in slice timing and head movement, coregistered to the T1 image and spatially (FWHM 6 mm) and temporally filtered (band pass 0.01–0.1 Hz). The BOLD signal originating from the white matter and ventricles, which is assumed to reflect physiological noise [27], and the six translation and rotation parameters obtained from the motion correction were deregressed from the BOLD signal.

The T1-weighted scan was parcellated into 82 cortical and subcortical brain regions using FreeSurfer v5.1.0 (The General Hospital Corporation, Boston MA, USA). Subsequently, a connectivity matrix was created by calculating the Pear-

son's correlation coefficient between the average (deregressed) BOLD time signal of each combination of two regions. Negative correlations were set to zero. The correlation values were thresholded, based on the average connectivity matrix, to obtain connectivity matrices with only the strongest connections. The number of included connections was varied, with sparsity levels ranging from 0 to 0.9 (0 is fully connected, whereas 1 indicates no connections).

Data analysis

The Brain Connectivity Toolbox [14] was employed to compute graph measures for each individual connectivity matrix. The clustering coefficient and the characteristic path length are commonly used to characterize the functional segregation and integration, respectively. The clustering coefficient quantifies the fraction of a node's neighbor that are also connected to each other. The characteristic path length is defined as the average shortest distance (the inverse correlation coefficient) between all pairs of nodes. As, in sparse networks, a single weak connection can result in a large, or even infinite average path lengths, global efficiency was computed instead of characteristic path length, which avoids this effect by using inverse path lengths [28].

One hundred null models of the connectivity matrices were computed by randomizing the connections of the original matrices, while preserving the degree and weight distribution [29]. The graph measures were divided by the mean global efficiency and clustering coefficient of these null models, providing a normalized global efficiency (Eg) and clustering coefficient (γ).

Statistical analysis

To test whether the clustering coefficient and global efficiency differed between the risk categories, an analysis of covariance (ANCOVA) was applied with the graph measures as outcome, cognitive risk category as fixed factor and age as covariate. Associations with cognition were assessed with linear regression analysis, with CVST time as outcome, and Eg or γ, age, and the percentage corrects answers in the Raven test as independent variables. To assess whether these results were affected by confounders, these analyses were repeated with gender, epilepsy severity score, or drug load (ratio of prescribed daily dose to defined daily dose [30]) added to the regression analyses as additional covariates. All statistical analyses were performed in MATLAB (version R2012b). P-values lower than 0.05 were considered significant.

Results

Patient characteristics

In total, 58 patients were included in this study. Three of these patients did not finish the procedures due to claustrophobia, resulting in 16 patients taking AEDs from the low-risk category, 34 taking AEDs from the intermediate-risk category, and 5 taking high-risk AEDs. The age and drug load were significantly higher in the intermediate-risk category than in the low-risk category (Table 4.1). Also the number of patients on polytherapy was significantly higher in the intermediate-risk category compared with the low-risk category, while the high- and low-risk categories significantly differed in number of patients on polytherapy. The risk categories did not differ in gender distribution, educational level, or epilepsy severity.

Neuropsychological assessment

The results of the CVST and the Raven task are summarized in Table 4.2. The CVST reaction time was slower than the normal range (range: 7.3 to 30.8 s, while the mean±sd was 10.3±4.1 s in normal population [32]). A significant effect of risk category on CVST reaction time was observed, which remained significant when controlling for age, gender, and global cognitive level (p=0.009, ANCOVA). Post hoc tests showed significant differences in CVST between the low- and intermediate-risk category (p=0.035, estimated adjusted mean difference 3.5 s), and between the low- and high-risk category (p=0.004, adjusted mean difference 7.8 s). No significant differences were found between the percentage correct answers Raven scores of the different risk categories.

Network topology

Of the 55 included patients, seven were excluded from further analysis: one patient was excluded because of excessive head motion (maximum head movement of 8.0 mm, while the maximum head movement was below 1.5 mm in all other patients), one because of a deeper large lesion mass, and five patients were excluded because of a failure to automatically parcellate the cortex, due to cortical abnormalities. The analysis was therefore performed on 48 patients: 15 patients taking AEDs from the low-risk category, 29 patients taking AEDs from the intermediate-risk category and 4 patients taking the high-risk medication. The maximum head displacement did not differ between the three risk categories. The functional networks were fully connected and showed small-world characteristics within the sparsity range 0.32–0.66 (which was defined as γ/λ significantly larger than one, with γ the nor-

Table 4.1. Patient characteristics for the three risk categories[a].

	Low-risk (n=16)	Intermediate-risk (n=34)	High-risk (n=5)
General			
Male/female	5/11 (31/69%)	16/18 (47/53%)	0/5 (0/100%)
Age (years)[b]	39.5±13.4	50.7±12.5*	42.4±15.8
Educational level[c]	5 (range 2–6)	5 (range 2–7)	5 (range 4–6)
Epilepsy-related			
Symptomatic/non-symptomatic epilepsy	2/14 (13/88%)	15/19 (44/56%)	0/5
Seizure frequency			
Weekly	0	1 (3%)	0
Monthly	4 (25%)	3 (9%)	0
Yearly	2 (13%)	6 (18%)	2 (40%)
Seizure free	10 (63%)	24 (71%)	3 (60%)
Years since epilepsy onset[b]	22.7±11.7	30.4±13.4	26.8±23.3
Epilepsy severity score[b]	1.4±0.8	1.2±1.0	1.0±0.7
AED-related			
Mono-/polytherapy	16/0	8/26 (24/77%)*	3/2 (60/40%)†
Medication type			
CBZ	0	17 (50%)	1 (20%)
LEV	7 (44%)	6 (18%)	0
LTG	9 (56%)	10 (29%)	1 (20%)
OXC	0	4 (12%)	0
PHT	0	16 (47%)	0
TPM	0	0	5 (100%)
VPA	0	7 (21%)	1 (20%)
Drug load[b,d]	1.3±0.6	1.8±0.7*	1.2±1.0

Differences between the risk groups were tested using a Fisher's exact test (gender, symptomatic epilepsy, number of different AEDs), a Mann-Whitney test (educational level, seizure frequency, epilepsy severity score), or a student's t-test (all remaining variables). *indicates significant differences between the low- and intermediate-risk category ($p<0.05$); †indicates differences between the low- and high-risk category ($p<0.05$).

[a]Low-risk: lamotrigine (LTG), levetiracetam (LEV); Intermediate-risk: valproate (VPA), carbamazepine (CBZ), oxcarbazepine (OXC) and phenytoin (PHT); High-risk: topiramate (TPM)

[b]mean±standard deviation

[c]Median (range). Scores are according to Verhage [31], range 1 (did not finish primary school) to 7 (Master's degree)

[d]The drug load is defined as the ratio of the prescribed daily dose to the defined daily dose [30].

malized clustering coefficient, and λ the normalized characteristic path length). Only the sparsity levels within this range were considered for further analyses. The ANCOVA test revealed significant effects of risk category on Eg at most sparsities within this sparsity range (Figure 4.1). Post hoc tests showed a significantly higher Eg for patients from the low-risk category (n=14) compared with the high-risk category (n=4), and for patients from the intermediate-risk category (n=29)

Table 4.2. Results of the neuropsychological investigation, represented as mean±standard deviation for each risk category.

	Cognitive test results	
	CVST (s)[a]	Raven[b]
Risk category		
Low-risk	11.5±2.9	71.7±10.3%
Intermediate-risk	15.7±6.4	73.2±10.1%
High-risk	20.2±6.7	71.7±3.1%
p-value[c]	0.008	0.85

[a]mean reaction time on the Computerized Visual Searching Task (CVST) [22]
[b]Percentage correct answers on the Raven Standard Progressive Matrices [24]
[c]Tested with ANOVA

compared with the high-risk category (n=4). Eg or γ did not differ significantly between patients from the low- and intermediate-risk categories (p>0.2 at all sparsity levels), and no significant associations were observed between γ or Eg and CVST time (p>0.15 at all sparsity levels). Gender, epilepsy severity score, or drug load were not significantly associated with the γ, Eg, or CVST reaction time, and the results of these adjusted analyses were consistent with the results of the analyses without these additional covariates (<10% change in effect size of the variable of interest).

Discussion

The current study investigated whether patients taking AEDs with a different risk for cognitive side effects have different functional brain topologies. To this end, we included epilepsy patients with chronic AED treatment with different risk profiles, i.e. a low-risk category, intermediate-risk, and high-risk category. Furthermore, we assessed whether cognitive problems, in terms of a decreased central information processing speed, could be associated with the functional brain organization.

A higher global efficiency was shown in patients taking TPM (n=4, the high-risk category), compared with patients taking the low- (n=14) and intermediate-risk AEDs (n=29). The directionality of this difference is strikingly, as this result seems to contradict the cognitive side effects of TPM. The global efficiency is suggested to be particularly important for more complex cognitive tasks, for which different brain areas are involved [33]. The 'better' global efficiency in TPM users might however be interpreted as a compensatory mechanism, or could be explained by a 'survivor effect'. As patients with side effects are more likely to switch to other



Figure 4.1. Mean clustering coefficient (A, C) and global efficiency (B, D) for each risk category. Both clustering coefficient and global efficiency are normalized, i.e. the measures are divided by the clustering coefficient and global efficiency of random networks. A and B show the graph measures as a function of sparsity, while B and D show the results at a single sparsity level. Error bars show standard deviations, while the asterisks indicate significant differences between the risk categories ($p<0.05$, with age included as covariate).

AEDs, it is likely that these patients are less vulnerable for cognitive problems. The higher global efficiency in the high-risk group might therefore reflect a lower susceptibility for cognitive side effects of these patients [34, 35]. However, these patients did have a lower processing speed compared with the other patients, which argues against this explanation and in favor of a compensatory mechanism.

No differences in graph measures were observed between the patients groups taking AEDs from the low- and from the intermediate-risk category. It is possible that the effects of TPM on brain organization are more pronounced compared with effects of other AEDs, but TPM can also have distinctive effects on brain organization. TPM is suggested to have a unique cognitive profile, with specific effects on verbal fluency. Moreover, it has multiple mechanisms of action, and both these mechanisms and its chemical structure differ from other AEDs [36].

Furthermore, no associations were found between processing speed and graph measures, in contrast to a previous study that showed not only associations between intellectual decline and a lowered clustering coefficient in patients with epilepsy, but also with increasing drug load [17]. The latter suggests that the intellectual decline (which was based on intelligence tests) was a side effect of the AED treatment, but this could also result from differences in epilepsy characteristics. That study included more patients with a high drug load (15% of the patients had a drug load higher than 3) than the current study (no drug loads higher than 3 in the included patients), thus it is possible that the effects on graph measures are only measureable in patients with higher drug loads or AEDs with high risks on cognitive complaints.

The measured information processing speed covered the whole range from normal to a clearly affected processing speed, and patients taking AEDs known to induce cognitive side effects, showed lower processing speeds than patients with lower risk AEDs. These results could therefore not explain the lack of associations between graph measures and information processing speed, or the lack of differences in graph measures between the low- and intermediate-risk category. Also no trends were shown, while the total number of participants (48), and the number of patients in the low- (16) and intermediate-risk categories (34) were relatively large, making it unlikely that this lack of findings were due to limited power.

All included patients in the current study were diagnosed with localization-related epilepsy. Epilepsy is associated with a decreased global efficiency and increased clustering coefficient, although some studies showed a decreased clustering coefficient in patients with epilepsy [37]. It is therefore plausible that the functional brain networks of all three groups of patients in this study were already altered compared with healthy participants, irrespective of AED treatment.

This study has several limitations. Although we tried to include comparable patient groups, the risk categories differed in age and drug load, suggesting that our

study population is biased. Therefore, the analyses were corrected for these characteristics by including age and drug load as covariates. Besides these characteristics, also other factors could have confounded our results, such as the location of the epileptic focus or effects of AEDs on the neurovascular coupling, which should be assessed in separate studies [38]. Finally, no information is available about changes over time and causality due to the cross-sectional design.

Conclusion

No differences in functional network graph measures could be detected between patients with epilepsy after chronic use of AEDs with a different risks on cognitive side effects. Only the four patients taking TPM, which has a high risk for developing cognitive side effects, showed a more efficient brain network topology, which might be a compensatory mechanism. Also no associations were found between the graph measures and the measured cognitive impairments, specifically slowing of central information processing. Alterations in functional brain network organization may be only subtle and measureable in patients with more severe cognitive side effects.

Acknowledgements

The authors thank R. Berting for his assistance with the image acquisition and M. Geerlings and J. Slenter for continuous hardware and software support.

References

[1] P. Perucca and F. G. Gilliam. Adverse effects of antiepileptic drugs. *The Lancet Neurology*, 11 (9):792–802, 2012.

[2] D. M. IJff and A. P. Aldenkamp. Cognitive side-effects of antiepileptic drugs. *Handb Clin Neurol.*, 111:707–718, 2013.

[3] C. Helmstaedter, A. P. Aldenkamp, G. A. Baker, A. Mazarati, P. Ryvlin, and R. Sankar. Disentangling the relationship between epilepsy and its behavioral comorbidities – the need for prospective studies in new-onset epilepsies. *Epilepsy Behav*, 31:43–7, 2014.

[4] H. P. Bootsma, L. Ricker, Y. A. Hekster, J. Hulsman, D. Lambrechts, M. Majoie, A. Schellekens, M. de Krom, and A. P. Aldenkamp. The impact of side effects on long-term retention in three new antiepileptic drugs. *Seizure*, 18(5):327–331, 2009.

[5] P. Kwan and M. J. Brodie. Neuropsychological effects of epilepsy and antiepileptic drugs. *The Lancet*, 357(9251):216–222, 2001.

[6] M. A. Rogawski and W. Loscher. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci*, 5 (7):553–64, 2004.

[7] T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, P. A. Hofman, M. C. Vlooswijk, R. P. Rouhl, A. J. de Louw, W. H. Backes, and J. F. Jansen. Metabolic and functional MR biomarkers of antiepileptic drug effectiveness: A review. *Neurosci Biobehav Rev*, 59:92–9, 2015.

[8] X. Li, R. Ricci, C. H. Large, B. Anderson, Z. Nahas, D. E. Bohning, and M. S. George. Interleaved transcranial magnetic stimulation and fMRI suggests that lamotrigine and valproic acid have different effects on corticolimbic activity. *Psychopharmacology (Berl)*, 209(3):233–44, 2010.

[9] H. Jokeit, M. Okujava, and F. G. Woermann. Carbamazepine reduces memory induced activation of mesial temporal lobe structures: a pharmacological fMRI-study. *BMC Neurol*, 1:6, 2001.

[10] B. Wandschneider, J. Stretton, M. Sidhu, M. Centeno, L. R. Kozák, M. Symms, P. J. Thompson, J. S. Duncan, and M. J. Koepp. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. *Neurology*, 83(17):1508–1512, 2014.

[11] J. F. Jansen, A. P. Aldenkamp, H. J. Marian Majoie, R. P. Reijs, M. C. de Krom, P. A. Hofman, M. Eline Kooi, K. Nicolay, and W. H. Backes. Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. *Epilepsy Behav*, 9(1):181–5, 2006.

[12] A. De Ciantis, M. Muti, C. Piccolini, M. Principi, A. Di Renzo, R. De Ciantis, D. Frondizi, G. Iannone, P. Ottaviano, and M. Piccirilli. A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. *Neurol Sci*, 29 Suppl 1: S141–3, 2008.

[13] C. L. Yasuda, M. Centeno, C. Vollmar, J. Stretton, M. Symms, F. Cendes, M. A. Mehta, P. Thompson, J. S. Duncan, and M. J. Koepp. The effect of topiramate on cognitive fMRI. *Epilepsy Res*, 105(1-2):250–5, 2013.

[14] M. Rubinov and O. Sporns. Complex network measures of brain connectivity: uses and interpretations. *Neuroimage*, 52(3):1059–69, 2010.

[15] M. P. van den Heuvel, C. J. Stam, R. S. Kahn, and H. E. Hulshoff Pol. Efficiency of functional brain networks and intellectual performance. *J Neurosci*, 29(23):7619–24, 2009.

[16] C. Giessing, C. M. Thiel, A. F. Alexander-Bloch, A. X. Patel, and E. T. Bullmore. Human brain functional network changes associated with enhanced and impaired attentional task performance. *J Neurosci*, 33(14):5903–14, 2013.

[17] M. C. G. Vlooswijk, M. J. Vaessen, J. F. A. Jansen, M. C. F. T. M. de Krom, H. J. M. Majoie, P. A. M. Hofman, A. P. Aldenkamp, and W. H. Backes. Loss of network efficiency associated with cognitive decline in chronic epilepsy. *Neurology*, 77(10):938–944, 2011.

[18] L. Bonilha, A. Tabesh, K. Dabbs, D. A. Hsu, C. E. Stafstrom, B. P. Hermann, and J. J. Lin. Neurodevelopmental alterations of large-scale structural networks in children with new-onset epilepsy. *Hum Brain Mapp*, 35(8):3661–72, 2014.

[19] Z. Haneef, H. S. Levin, and S. Chiang. Brain graph topology changes associated with anti-epileptic drug use. *Brain Connect*, 5(5):284–91, 2015.

[20] T. M. van Veenendaal, D. M. IJff, A. P. Aldenkamp, R. H. C. Lazeron, N. A. J. Puts, R. A. E. Edden, P. A. M. Hofman, A. J. A. de Louw, W. H. Backes, and J. F. A. Jansen. Glutamate concentrations vary with antiepileptic drug use and mental slowing. *Epilepsy & Behavior*, 64: 200–205, 2016.

[21] S. R. Samarasekera, C. Helmstaedter, and M. Reuber. Cognitive impairment in adults with epilepsy: The relationship between subjective and objective assessments of cognition. *Epilepsy Behav*, 52(Pt A):9–13, 2015.

[22] A. P. Aldenkamp, J. Arends, N. M. de la Parra, and E. J. W. Migchelbrink. The cognitive impact of epileptiform EEG discharges and short epileptic seizures: relationship to characteristics of the cognitive tasks. *Epilepsy & Behavior*, 17(2):205–209, 2010.

[23] D. M. IJff and A. P. Aldenkamp. *Comorbidities of treatment with antiepileptic drugs*, pages 424–36. New York: McGraw-Hill Professional, 2012.

[24] J. Raven, J. C. Raven, and J. H. Court. Manual for Raven's Progressive Matrices and Vocabulary Scales. Section 3: The Standard Progressive Matrices. *San Antonio, TX: Harcourt Assessment*, 2000.

[25] E. Grevers, L. E. Breuer, I. Jff DM, and A. P. Aldenkamp. Mental slowing in relation to epilepsy and antiepileptic medication. *Acta Neurol Scand*, 2015.

[26] E. van Diessen, S. J. Diederen, K. P. Braun, F. E. Jansen, and C. J. Stam. Functional and structural brain networks in epilepsy: what have we learned? *Epilepsia*, 54(11):1855–65, 2013.

[27] K. Murphy, R. M. Birn, and P. A. Bandettini. Resting-state fMRI confounds and cleanup. *Neuroimage*, 80:349–59, 2013.

[28] E. T. Bullmore and D. S. Bassett. Brain graphs: graphical models of the human brain connectome. *Annu Rev Clin Psychol*, 7:113–40, 2011.

[29] M. Rubinov and O. Sporns. Weight-conserving characterization of complex functional brain networks. *Neuroimage*, 56(4):2068–79, 2011.

[30] M. W. Lammers, Y. A. Hekster, A. Keyser, H. Meinardi, W. O. Renier, and H. van Lier. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. *Epilepsia*, 36(5):440–446, 1995.

[31] F. Verhage. *Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar*. Van Gorcum Assen, 1964.

[32] W. Alpherts and A. P. Aldenkamp. FePsy: the iron psyche. *Heemstede: Instituut voor Epilepsiebestrijding*, 1994.

[33] C. Giessing and C. M. Thiel. Pro-cognitive drug effects modulate functional brain network organization. *Front Behav Neurosci*, 6:53, 2012.

[34] A. Hahn, G. S. Kranz, R. Sladky, S. Ganger, C. Windischberger, S. Kasper, and R. Lanzenberger. Individual diversity of functional brain network economy. *Brain Connect*, 5(3):156–65, 2015.

[35] E. Santarnecchi, S. Rossi, and A. Rossi. The smarter, the stronger: Intelligence level correlates with brain resilience to systematic insults. *Cortex*, 64:293–309, 2015.

[36] M. Mula. Topiramate and cognitive impairment: evidence and clinical implications. *Ther Adv Drug Saf*, 3(6):279–89, 2012.

[37] E. van Diessen, W. J. Zweiphenning, F. E. Jansen, C. J. Stam, K. P. Braun, and W. M. Otte. Brain network organization in focal epilepsy: A systematic review and meta-analysis. *PLoS One*, 9(12):e114606, 2014.

[38] I. Kida, A. J. Smith, H. Blumenfeld, K. L. Behar, and F. Hyder. Lamotrigine suppresses neurophysiological responses to somatosensory stimulation in the rodent. *Neuroimage*, 29(1):216–24, 2006.

Part II

Methodological studies

Chapter 5

Glutamate quantification by PRESS or MEGA-PRESS: accuracy, repeatability, and concordance

T. M. van Veenendaal, W. H. Backes, F. C. G. van Bussel, R. A. E. Edden, N. A. J. Puts, A. P. Aldenkamp, J. F. A. Jansen, *Submitted*

Chapter 6

High field imaging of large-scale neurotransmitter networks: proof of concept and initial application to epilepsy

T. M. van Veenendaal, W. H. Backes, D. H. Y. Tse, T. W. J. Scheenen, D. W. Klomp, P. A. M. Hofman, R. P. W. Rouhl, M. C. G. Vlooswijk, A. P. Aldenkamp, J. F. A. Jansen, *Submitted*

Chapter 7

General discussion

Continuous evaluation of clinical studies, improvement of existing techniques, and explorations of novel measurement techniques are necessary to increase insights into epilepsy and improve its treatment. In this context, a number of clinical and methodological studies were set out in the current thesis, for which the aim was twofold. The first aim was to identify neuronal substrates of cognitive side effects of antiepileptic drugs (AEDs) measured with currently available magnetic resonance (MR) techniques. The second aim was to develop and apply magnetic resonance techniques that may give new insights in the role of neurotransmitters in epilepsy and impaired cognition, an often occurring co-morbidity of epilepsy.

Considering the first aim, a literature review (Chapter 2) and two clinical MR studies on patients with epilepsy were performed, assessing the associations between AED use, cognition, and neurotransmitter concentrations (Chapter 3) or functional brain network organization (Chapter 4). Considering the second aim, two studies have been performed. Chapter 5 describes the results of a study performed on the accuracy, repeatability, and concordance of two MR spectroscopy (MRS) sequences commonly applied to measure concentrations of the neurotransmitter glutamate. In Chapter 6, the spatial cerebral distribution of the neurotransmitters glutamate and GABA, was investigated and the concept of neurotransmitter networks was introduced.

Three questions relevant for these five chapters, were:

(i) How do AEDs affect the brain, and how is that related to cognitive side effects?

(ii) How do local measurements provide information on distal effects and brain networks?

(iii) And how valid are the advanced measurement techniques applied?

The results of the five chapters together will be discussed according to these three questions in the following sections, ending with a general conclusion.

Cognitive side effects of antiepileptic drugs

Current findings

To identify neuronal substrates of cognitive side effects of AEDs, two different techniques were employed: (i) MRS, that enables *in vivo* measurements of glutamate and γ-aminobutyric acid (GABA), which are the most common excitatory and inhibitory neurotransmitters in the brain, respectively, and (ii) functional MR imaging (fMRI), which provides measures indicative of brain activity.

Previous MRS studies showed that AEDs with a known GABAergic mechanism of action, such as topiramate and vigabatrin, increased cerebral GABA concentrations. Effects on glutamate concentrations were assessed by only a few studies so far and are therefore currently not known (Chapter 2). By combining neuropsychological testing with MRS, we showed that lower glutamate concentrations could be linked to cognitive slowing in patients with epilepsy taking AEDs (Chapter 3).

At neuronal scale, AEDs are claimed to suppress (hyper) excitability. However, at brain level fMRI studies showed that brain activity can either be decreased, remain unaffected or can even be increased (Chapter 2). The impact of these effects were AED type dependent and also differed between various brain regions. However, previous studies suggested that not the brain activity per se, but coordinated brain activity between different brain regions, i.e. functional brain networks, are important for cognitive functioning [1–3]. Therefore we performed a study of these functional brain networks and AED use in relation to the existing cognitive problems (Chapter 4). In this study, surprisingly no associations between cognitive slowing and brain network organization were found, and only the small subgroup of patients taking AEDs from the highest risk group (n=4) showed altered network measures compared with patients taking AEDs from the low- or intermediate-risk group. Based on this study, we concluded that the effect of AEDs on functional brain network organization may be subtle and only detectable in patients with more severe cognitive side effects.

Mechanisms of action

Currently, more than twenty different AEDs are available with different mechanisms of action, which can be distinguished in three main mechanisms: GABAergic, glutamatergic, and voltage-gated channels [4]. Cognitive side effects of AEDs are likely a direct effect of these mechanisms [5]. Side effects are often dose-dependent and occur only during the use of AEDs and disappear if AED use is discontinued. It has been suggested that mainly GABAergic mechanisms induce cognitive side effects, but also these effects can be caused by AEDs with other mechanisms of action [6]. For instance, the AED phenytoin targets voltage-gated sodium channels, but is also known to affect attention, memory and mental speed [7]. These factors suggest that cognitive side effects are a result of attenuated neuronal activity with AED use. The observed association between lower glutamate concentrations and cognitive slowing supports this hypothesis, as glutamate concentrations are likely related to excitatory activity [8]. However, specific mechanisms might attribute to specific cognitive complaints: GABAergic mechanisms are hypothesized to affect attention, while glutamatergic mechanisms might have a negative effect on learning

and memory due to their interference with NMDA receptor, important in learning and memory [6].

Methodological considerations

The distinction between cognitive problems due to epilepsy itself or due to treatment is a major problem when assessing cognitive side effects of AEDs. Epilepsy is a very heterogeneous disease, with a large variety in causes (varying from tumors to genetic defects), affected regions in the brain, number and type of seizures, and age of onset [9]. All these effects might affect cognition differently [10], and also the selection of appropriate AEDs is based on some of these factors [9]. A disadvantage of the observational nature of the studies described in this thesis is therefore the possible confounding effects of the various characteristics of the epilepsy itself.

Another consideration about the design of the study is the distinction of the AEDs in low, intermediate, and high-risk categories, irrespective of the mechanism of action. This can be justified by the cognitive side effects, but the effects of AEDs on neurotransmitter concentrations, or on functional brain organization, might depend on the mechanism of action. More studies are therefore necessary to assess these associations in individual AEDs.

Clinical implications and future directions

AED treatment aims to achieve seizure freedom without inducing adverse effects. Unfortunately, this treatment is often accompanied with side effects, of which cognitive problems are an important category [11]. Currently, we are neither able to predict nor to explain which patient will suffer from side effects. More insights into this topic might improve AED treatment in two ways: first, it might help clinical decision-making if a neurologists knows beforehand if a patient is vulnerable to develop cognitive side effects, and second, it might provide guidance in the search for new AEDs with less cognitive side effects.

The associations of brain glutamate levels, AED use, and cognition described in Chapter 3 might give rise to more focused studies to predict cognitive problems in patients with epilepsy. For this purpose, differences in glutamate levels between patients with and without side effects should be apparent before start of treatment. Therefore it is important to assess the relationship between glutamate levels and cognition both before and during AED treatment, preferably in longitudinal studies.

The association of cognitive side effects with neuronal activity, should be further assessed and specified using other techniques than MR. *In vitro* studies have been used to assess effects of AED use on neuronal activity and synaptic plasticity,

which can be related to the known side effects of AEDs [12, 13]. Electroencephalography (EEG) can be applied to measure associations of AEDs, cognition and brain activity patterns [14], while positron emission tomography (PET) might give additional information about receptor binding. PET tracers can be applied to measure the affinity of receptors, such as the radiotracer ^{11}C-flumazenil to determine the $GABA_A$ receptor binding [15].

fMRI appears to be the most obvious MR technique to measure neuronal activity, but has some disadvantages when studying AED effects on the brain. fMRI measures the blood oxygenation level dependent (BOLD) activity, which is only indirectly related to brain activity. fMRI is mostly applied to measure task-related activation patterns. Unfortunately, the intrinsic signal responses to the task are little and also the relative change in BOLD signal due to medication is often low, which makes fMRI less suitable to measure global changes in activity [16]. BOLD signals are also sensitive to possible (unwanted) effects of medication on blood flow, and fMRI studies of AED effects should therefore be combined with techniques to measure this blood flow, such as arterial spin labeling (ASL) [16].

Local measurements, distal effects, and brain networks

Current findings

A common theme in this thesis is the connection between local measurements and distal effects, and between local measurements and brain networks. Two questions that frequently arose are:

(i) Does a local finding also reflect distal abnormalities?

(ii) Are characteristics of single regions related to characteristics of other or even global regions?

With MRS, the voxel-of-interest is often placed occipitally, because the highest signal quality can be obtained in that region [17, 18]. This was also the case in Chapter 3, while in this study, the measured glutamate concentrations were associated with information processing speed, a cognitive function that strongly involves the prefrontal cortex [19]. An unanswered question is how these occipital measurements are associated with functions that involve the prefrontal brain regions.

Chapter 6 presents a study that attempts to extend from local MRS measurements to global brain networks. Glutamate and GABA concentrations were measured in 21 distributed brain areas, and connections between these areas were

computed and analyzed. While these neurotransmitter concentrations showed correlations between several distant regions, this correlation was absent between other regions, i.e. we could speak of large-scale spatial organization, so-called networks, for both neurotransmitters. We furthermore measured a higher neurotransmitter connectivity in patients with epilepsy than in healthy participants.

Conceptual background

We assumed that areas that share characteristics, are likely to be connected somehow, a phenomenon known as the 'homophily principle' in social sciences [20]. For two connected areas, the neurotransmitter concentration in one area is positively or negatively associated with the other area [21]. The meaning of these correlations, and mechanisms causing these correlations, are currently unknown, but are likely related to an underlying functional organization of concerted brain activity. While glutamate can be related to excitatory activity, GABA concentrations are related to the fraction of GABAergic neurons [8]. Concentrations of both neurotransmitters have previously been associated with functional connectivity [22]. It is plausible, that areas with shared functionality, show correlated activity, and therefore reveal correlations in neurotransmitter concentrations underlying this activity.

This network concept could explain the association between occipital glutamate concentrations and prefrontal functions, as the glutamate network described in Chapter 6 indeed showed connections between the occipital grey matter and prefrontal white matter. In this scenario, AEDs have a prefrontal effect, and due to that effect the occipital glutamate concentrations are altered, or vice versa: AEDs alter occipital glutamate levels, which affect prefrontal areas, that in its turn affects cognition.

However, as the location of the epileptic focus is not an important factor in the decision of an appropriate AED [9], we can speculate that AEDs have a similar effect on all brain areas. Thus, in our study, an alternative possibility is that the occipital changes in glutamate concentrations reflect global changes.

Methodological considerations

As the study of neurotransmitter networks is a first exploration of this concept, there are several methodological considerations, partly due to scanning difficulties (coarse spatial resolution, long scanning time, scanning artifacts, etc.) and partly as result of the analyses (e.g. how to compensate for differences in grey and white matter content). A major drawback is that at this moment, the networks are formulated at group level instead of individual level. Alternative methods are therefore

required to associate individual clinical measures, such as seizure frequency, drug load or cognitive co-morbidity, to neurotransmitter networks.

As already mentioned, the precise mechanisms underlying the neurotransmitter connections are unknown, and the method provides no actual physical connections, but an implied connection through neuronal correlations of neurotransmitters. Unfortunately, all methods to study *in vivo* brain networks use indirect measures for connections. However, each modality provides unique information about brain functioning, thus the most complete information can be obtained by combining measurements from all different modalities [23].

Clinical implications and future directions

The neurotransmitter connectivity appeared to be higher in patients with epilepsy than healthy participants. Epilepsy is a disease in which large-scale cortical networks are disrupted. Crucial for these networks are inhibitory neurons, synaptic transmission, and neuronal properties [9]. Neurotransmitter networks might be able to give additional information about network dysfunction in epilepsy, as GABA and glutamate concentrations reflect inhibitory neurons and neuronal activity. Future studies might focus on the relation between AED use and neurotransmitter network alterations, because some AEDs alter GABA concentrations (Chapter 2) and cognitive problems were related to glutamate concentrations (Chapter 3). Finally, neurotransmitter network dysfunction might be related to cognitive problems in epilepsy. Studying neurotransmitter networks might therefore help to understand and manipulate the cortical networks in epilepsy (for instance with AEDs), but also in other neurological and psychiatric diseases [24].

Also single-voxel MRS studies might benefit from knowledge of neurotransmitter networks. Neurotransmitter and other neurometabolite concentrations are commonly measured in occipital regions, while the results are associated with cognitive functions [25–27]. Information about the coherence between these neurometabolite concentrations in different brain regions, both in healthy participants and patients, might contribute to the interpretation of these studies.

Validation of MR techniques

Overview thesis

Before novel techniques can be used for clinical or research purposes, validation of these techniques is necessary. For this thesis, we can distinguish two aspects that need validation: firstly, the applied acquisition techniques, i.e. can MRS measure the correct metabolites and concentrations, and can fMRI correctly detect brain

activation? And secondly, the applied analyses methods need validation, especially when discussing brain connectivity.

MR spectroscopy (as applied in Chapter 3) is a commonly used technique to measure *in vivo* neurotransmitter concentrations. The validity of the applied method to measure glutamate concentrations was further assessed in Chapter 5. This chapter presents a study to compare two commonly applied sequences (PRESS and MEGA-PRESS) that enable *in vivo* glutamate concentrations. The results showed that, although both PRESS as MEGA-PRESS had a sufficient accuracy (in phantoms) and *in vivo* reproducibility, the *in vivo* concordance between those sequences was lower than expected. The cause of this low concordance is currently unknown, as both methods could be applied to measure glutamate concentrations. Future studies interested in glutamate measurements, might choose between these two commonly used and easily to implement sequences. While PRESS has a shorter duration and better repeatability than MEGA-PRESS, MEGA-PRESS enables also GABA measurements. Studies interested in both GABA and glutamate, with a limited time, might therefore choose to only perform a MEGA-PRESS scan.

A neurotransmitter network, described in Chapter 6, is a newly introduced concept. As only a correlation on group level is presented, and no individual network measures, no reproducibility measures of network measures could be presented. However, five participants were measured twice, and the results were robust for these within-subjects variations. Measurements of neurotransmitter concentrations showed a moderate to good reproducibility for these participants.

Implications and directions for further studies

At this moment, the study of neurotransmitter networks is still in its infancy. Methodological improvements and necessary validation are required before the measurement of neurotransmitter networks can be applied in daily clinical practice. Therefore, neurotransmitter networks should be further validated in research studies, starting with repeating the current study which larger sample sizes to confirm the current findings.

Further validation of functional brain network analyses was out of the scope of this thesis. However, several arbitrary choices have to be made during this analyses, which can largely affect the result of the study, such as the handling of negative weighted connections [28]. The results described in Chapter 4 differ from those of a previous study, which did find associations between functional brain network organization, AED use (i.e. drug load) and cognitive functioning (IQ) [29]. This latter study included patients with higher drug loads, thus these patients might have suffered from more severe side effects. However, this difference might

also result from differences in analyses methods. Further evaluation of different analyses methods for functional networks is therefore required, and differences in these methods between studies should be considered if comparing these studies.

Conclusion

The studies described in this thesis aimed to identify neuronal substrates of cognitive side effects of AEDs, and to study novel MR techniques that may give new insights on the neurotransmitter function in epilepsy and cognition. The demonstrated associations of glutamate concentrations, AED use, and cognition might be suitable as biomarker for cognitive side effects of AED treatment. Two different sequences to measure these glutamate concentrations (i.e. PRESS and MEGA-PRESS) were studied, and the results showed that both sequences can be employed to measure *in vivo* glutamate concentrations. Finally, the concept of neurotransmitter networks was introduced, which provides a new dimension to further study associations of epilepsy, AED use and cognition.

References

[1] C. Giessing, C. M. Thiel, A. F. Alexander-Bloch, A. X. Patel, and E. T. Bullmore. Human brain functional network changes associated with enhanced and impaired attentional task performance. *J Neurosci*, 33(14):5903–14, 2013.

[2] H. J. Park and K. Friston. Structural and functional brain networks: from connections to cognition. *Science*, 342(6158):1238411, 2013.

[3] M. P. van den Heuvel, C. J. Stam, R. S. Kahn, and H. E. Hulshoff Pol. Efficiency of functional brain networks and intellectual performance. *J Neurosci*, 29(23):7619–24, 2009.

[4] M. A. Rogawski and W. Loscher. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci*, 5 (7):553–64, 2004.

[5] P. Perucca and F. G. Gilliam. Adverse effects of antiepileptic drugs. *The Lancet Neurology*, 11 (9):792–802, 2012.

[6] R. Sankar and G. L. Holmes. Mechanisms of action for the commonly used antiepileptic drugs: Relevance to antiepileptic drug–associated neurobehavioral adverse effects. *Journal of Child Neurology*, 19(1 suppl):S6–S14, 2004.

[7] D. M. IJff and A. P. Aldenkamp. *Comorbidities of treatment with antiepileptic drugs*, pages 424–36. New York: McGraw-Hill Professional, 2012.

[8] C. D. Rae. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. *Neurochem Res*, 39(1):1–36, 2014.

[9] J. S. Duncan, J. W. Sander, S. M. Sisodiya, and M. C. Walker. Adult epilepsy. *The Lancet*, 367 (9516):1087–1100, 2006.

[10] C. E. Elger, C. Helmstaedter, and M. Kurthen. Chronic epilepsy and cognition. *The Lancet Neurology*, 3(11):663–672, 2004.

[11] R. S. Fisher, B. G. Vickrey, P. Gibson, B. Hermann, P. Penovich, A. Scherer, and S. Walker. The impact of epilepsy from the patient's perspective II: views about therapy and health care. *Epilepsy Research*, 41(1):53–62, 2000.

[12] C. Sgobio, V. Ghiglieri, C. Costa, V. Bagetta, S. Siliquini, I. Barone, M. Di Filippo, F. Gardoni, E. D. Gundelfinger, M. Di Luca, B. Picconi, and P. Calabresi. Hippocampal synaptic plasticity,

memory, and epilepsy: effects of long-term valproic acid treatment. *Biol Psychiatry*, 67(6):567–74, 2010.

[13] P. J. West, G. W. Saunders, G. J. Remigio, K. S. Wilcox, and H. S. White. Antiseizure drugs differentially modulate theta-burst induced long-term potentiation in C57BL/6 mice. *Epilepsia*, 55(2):214–223, 2014.

[14] M. C. Salinsky, L. M. Binder, B. S. Oken, D. Storzbach, C. R. Aron, and C. B. Dodrill. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. *Epilepsia*, 43(5): 482–490, 2002.

[15] O. M. Weber, A. Verhagen, C. O. Duc, D. Meier, K. L. Leenders, and P. Boesiger. Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. *Magnetic resonance imaging*, 17(3):417–425, 1999.

[16] B. Wandschneider and M. J. Koepp. Pharmaco fMRI: Determining the functional anatomy of the effects of medication. *Neuroimage Clin*, 12:691–697, 2016.

[17] C. J. Evans, N. A. Puts, S. E. Robson, F. Boy, D. J. McGonigle, P. Sumner, K. D. Singh, and R. A. Edden. Subtraction artifacts and frequency (mis-)alignment in J-difference GABA editing. *J Magn Reson Imaging*, 38(4):970–5, 2013.

[18] N. A. Puts and R. A. Edden. In vivo magnetic resonance spectroscopy of GABA: a methodological review. *Prog Nucl Magn Reson Spectrosc*, 60:29–41, 2012.

[19] R. Cabeza and L. Nyberg. Imaging cognition II: An empirical review of 275 PET and fMRI studies. *Journal of cognitive neuroscience*, 12(1):1–47, 2000.

[20] Ö. Şimşek and D. Jensen. Navigating networks by using homophily and degree. *Proc Natl Acad Sci U S A*, 105(35):12758–62, 2008.

[21] J. W. Pan, D. D. Spencer, R. Kuzniecky, R. B. Duckrow, H. Hetherington, and S. S. Spencer. Metabolic networks in epilepsy by MR spectroscopic imaging. *Acta Neurol Scand*, 126(6):411–20, 2012.

[22] N. W. Duncan, C. Wiebking, and G. Northoff. Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans – a review of multimodal imaging studies. *Neurosci Biobehav Rev*, 47C:36–52, 2014.

[23] A. Fornito, A. Zalesky, and M. Breakspear. Graph analysis of the human connectome: promise, progress, and pitfalls. *NeuroImage*, 80:426–44, 2013.

[24] S. S. Spencer. Neural networks in human epilepsy: evidence of and implications for treatment. *Epilepsia*, 43(3):219–227, 2002.

[25] A. J. Ross and P. S. Sachdev. Magnetic resonance spectroscopy in cognitive research. *Brain Res Rev*, 44(2-3):83–102, 2004.

[26] K. Sandberg, J. U. Blicher, M. Y. Dong, G. Rees, J. Near, and R. Kanai. Occipital GABA correlates with cognitive failures in daily life. *Neuroimage*, 87:55–60, 2014.

[27] F. C. van Bussel, W. H. Backes, P. A. Hofman, N. A. Puts, R. A. E. Edden, M. P. van Boxtel, M. T. Schram, C. D. Stehouwer, J. E. Wildberger, and J. F. A. Jansen. Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning. *Medicine (Baltimore)*, 95 (36):e4803, 2016.

[28] A. Weissenbacher, C. Kasess, F. Gerstl, R. Lanzenberger, E. Moser, and C. Windischberger. Correlations and anticorrelations in resting-state functional connectivity MRI: a quantitative comparison of preprocessing strategies. *NeuroImage*, 47(4):1408–16, 2009.

[29] M. C. G. Vlooswijk, M. J. Vaessen, J. F. A. Jansen, M. C. F. T. M. de Krom, H. J. M. Majoie, P. A. M. Hofman, A. P. Aldenkamp, and W. H. Backes. Loss of network efficiency associated with cognitive decline in chronic epilepsy. *Neurology*, 77(10):938–944, 2011.

Addendum

Summary

Epilepsy is a neurological disease which is characterized by unprovoked recurrent seizures, during which the brain shows abnormal and excessive neuronal activity. The majority of the patients use antiepileptic drugs (AEDs) to suppress epileptic seizures. Unfortunately, these AEDs also induce adverse effects, such as cognitive problems.

The brain can be considered as a network, encompassing neurons which are connected via synapses. It is assumed that the integrity of brain networks is important for cognitive functioning, and that this integrity is affected in neurological diseases as epilepsy. Different magnetic resonance (MR) techniques can be employed to assess different aspects of brain connectivity: functional MR imaging (fMRI) enables the assessment of functional brain networks, i.e. the framework of all, functionally connected brain areas, while MR spectroscopy (MRS) enables measurements of the neurotransmitters GABA and glutamate, the most abundant inhibitory and excitatory neurotransmitters in the brain, respectively. The aim of this thesis, as described in **Chapter 1**, was to further assess the associations between brain connectivity and cognitive problems in epilepsy.

In **Chapter 2**, an overview is given of previous MR studies that assessed effects of AEDs on the brain. MRS studies showed that AEDs with GABAergic mechanisms of action (such as topiramate and vigabatrin) increase the cerebral GABA concentrations. Effects on glutamate concentrations were thus far less frequently assessed and therefore not known conclusively. **Chapter 2** also discussed fMRI studies of AED effects. Although at neuronal level, AEDs aim to suppress (hyper) excitability, fMRI studies showed that at the brain level, brain activity can be decreased, but also unaffected or even increased. The effects of AEDs on brain activity differed between AED-type and brain regions.

Chapter 3 and **4** describe two studies that assessed associations between AEDs, cognitive problems, and *in vivo* neurotransmitter levels or brain network organization, respectively. For these studies, three groups of patients on chronic AED treatment were included: One group using AEDs with a low risk for cognitive side effects (lamotrigine or levetiracetam, n=16), one group using AEDs with an intermediate risk for cognitive side effects (carbamazepine, oxcarbazepine, phenytoin or valproate, n=34), and a group using AEDs with a high risk for cognitive side effects (topiramate, n=5). All patients underwent cognitive testing and MR scan-

ning. The Visual Computerized Searching Task (CVST) was applied to measure complex information processing speed, which is often affected by AED use. MRS was performed to measure *in vivo* neurotransmitter levels, and the brain network organization was measured using resting-state fMRI.

The associations between AEDs, cognitive problems, and neurotransmitter levels are described in **Chapter 3**. Patients with decreased processing speeds showed lower glutamate concentrations than patients with a normal processing speed. Furthermore, the glutamate concentrations were also significantly lower in the high and intermediate-risk category than in the low-risk category. No significant associations were found between GABA and information processing speed or risk category. Based on this study, we concluded that lower glutamate concentrations are related to AED use and slow down central information processing in patients with epilepsy.

Chapter 4 describes associations between AEDs, cognition, and functional brain network measures. Two measures were described: the clustering coefficient and the global efficiency, which are measures for functional segregation and integration, respectively. No associations were observed between information processing speed and these brain network measures, and only the high-risk category showed an increased global efficiency, which might be due to compensatory mechanisms. Alterations in functional brain network organization may be only subtle in the patients studied and may become measureable in patients with more severe cognitive side effects.

For further evaluation, MR techniques were studied that may give new insights in epilepsy and cognition. **Chapter 5** presents a study that evaluated different MRS methods to measure glutamate levels. Although not specifically designed for this purpose, PRESS and MEGA-PRESS sequences are both often used to measure glutamate. PRESS is a commonly applied method to measure neurometabolites, but is not able to measure GABA concentrations, while MEGA-PRESS allows for quantification of GABA. **Chapter 5** compares the accuracy, repeatability, and concordance of these sequences. Phantom experiments showed a good accuracy for both sequences. The repeatability was tested in five healthy participants and was sufficient in both sequences, but was better in PRESS than in MEGA-PRESS. However, the concordance between the sequences was only moderate (r=0.4), which might be due to macromolecule contamination in the PRESS or MEGA-PRESS spectra. Based on this study, we concluded that MEGA-PRESS can be used to combine GABA and glutamate measurements, albeit at a cost of lower repeatability compared with PRESS.

Chapter 6 describes a new method to assess brain networks based on metabolic information, in particular glutamate, GABA, and N-acetylaspartate measurements.

Many clinical neuroimaging studies are focused on altered structural or functional brain connectivity. However, these studies cannot provide direct information on the defective neurons or the linked neurotransmitter disbalance, which underlies abnormal neuronal activity. Therefore, the concept of 'neurotransmitter networks' was introduced. Areas were considered connected if the Pearson's correlation coefficient was significant between those areas, across the participants.

This concept was tested in fifteen healthy participants and ten patients with cryptogenic localization related epilepsy. In the healthy participants, 21%, 19%, and 26% of the possible connected areas showed a significant correlation for glutamate, GABA, and NAA, respectively. These connections can be conceptualized as 'metabolic brain networks'. When comparing networks from patients with epilepsy to those from healthy participants, an increased glutamate and GABA connectivity was found in the epilepsy group. We concluded that these neurotransmitter networks, and the increased neurotransmitter connectivity in patients with epilepsy, should be further explored to increase insights into epilepsy.

This thesis is finished with a general discussion in **Chapter 7**. This chapter provides a general overview of the main findings in this thesis, discusses these findings in a broader perspective and provides recommendations for further research.

Samenvatting

Epilepsie is een neurologische aandoening die gekarakteriseerd wordt door niet-uitgelokte, herhaald optredende aanvallen. Tijdens deze aanvallen vertoont het brein abnormale excessieve neuronale activiteit. De meerderheid van de patiënten gebruikt anti-epileptica om epileptische aanvallen te onderdrukken. Deze medicatie zorgt echter ook voor bijwerkingen, waaronder cognitieve problemen.

Het brein kan worden gezien als een netwerk bestaande uit neuronen die verbonden zijn via synapsen. Er wordt aangenomen dat de integriteit van dit hersennetwerk belangrijk is voor het cognitief functioneren, maar afwijkend is als sprake is van epilepsie. Verschillende magnetische resonantietechnieken zijn beschikbaar om de hersennetwerken te onderzoeken: functionele magnetische resonantie imaging (fMRI) maakt het mogelijk om functionele hersennetwerken te onderzoeken, terwijl met magnetische resonantie spectroscopie (MRS) de concentraties van de meest voorkomende activerende en remmende neurotransmitters in het brein (glutamaat en GABA) gemeten kunnen worden. Het doel van dit proefschrift, zoals beschreven in **hoofdstuk 1**, was om de samenhang tussen hersenconnectiviteit en cognitieve problemen als gevolg van epilepsie verder te onderzoeken.

Hoofdstuk 2 geeft een overzicht van eerdere MR studies die effecten van anti-epileptica op het brein hebben onderzocht. MRS studies hebben aangetoond dat anti-epileptica met GABAerge werkingsmechanismen (zoals topiramaat en vigabatrine) de GABA-concentraties in het brein verhogen. Het effect op glutamaatconcentraties is minder vaak onderzocht en daardoor niet duidelijk. Ook fMRI studies naar effecten van anti-epileptica op het brein worden besproken in **hoofdstuk 2**. Op celniveau hebben anti-epileptica als doel de (hyper)excitabiliteit te onderdrukken. Echter, fMRI studies hebben aangetoond dat op breinniveau, anti-epileptica hersenactiviteit kunnen onderdrukken, maar ook onaangedaan laten of zelfs stimuleren. De precieze effecten van anti-epileptica op de hersenactiviteit verschilden per type anti-epilepticum en hersengebied.

Hoofdstuk 3 en **4** beschrijven twee studies waarin de samenhang tussen langdurig gebruik van anti-epileptica, cognitieve problemen, en *in vivo* neurotransmitterconcentraties op hersennetwerkorganisatie onderzocht is. Voor deze studies zijn drie groepen epilepsiepatiënten geïncludeerd: De eerste groep bestond uit patiënten die anti-epileptica gebruiken met een laag risico op bijwerkingen (lamotrigine of levetiracetam, n = 16). De tweede groep bestond uit patiënten die anti-epileptica

gebruiken met een gemiddeld risico op cognitieve bijwerkingen (carbamazepine, fenytoïne, oxcarbazepine of valproaat, n=34), terwijl de derde groep bestond uit patiënten die anti-epileptica gebruiken met een hoog risico op cognitieve bijwerkingen (topiramaat, n=5). Alle patiënten ondergingen cognitieve testen en een MR scan. De Computerized Visual Searching Task (CVST) is gebruikt om de verwerkingssnelheid van complexe informatie te meten, een cognitieve functie die vaak is aangedaan door anti-epileptica. Neurotransmitterconcentraties zijn gemeten met behulp van MRS, en de organisatie van de hersennetwerken in rust zijn met behulp van fMRI gemeten.

De samenhang tussen anti-epileptica, cognitieve problemen, en neurotransmitterconcentraties wordt beschreven in **hoofdstuk 3**. De glutamaatconcentratie bleek positief gecorreleerd met de informatieverwerkingssnelheid. Met andere woorden, patiënten met een lagere informatiesnelheid, hadden ook een lagere glutamaatconcentratie. Verder was deze concentratie significant lager in de patiënten die medicatie met een hoog of gemiddeld risico op bijwerkingen gebruikten, dan in de patiënten die medicatie met een laag risico op bijwerkingen gebruikten. Tussen de GABA-concentratie en informatieverwerkingssnelheid, of tussen de GABA-concentratie en risicocategorie, waren geen significante associaties. Gebaseerd op deze resultaten concludeerden we dat lagere glutamaatconcentraties gerelateerd zijn aan het gebruik van anti-epileptica en een vertraagde informatieverwerking in epilepsiepatiënten.

Hoofdstuk 4 beschrijft de samenhang tussen anti-epileptica, cognitie, en breinnetwerkmaten. Twee verschillende maten werden beschreven: de clustercoëfficiënt en de globale efficiëntie, welke maten zijn voor de respectievelijke functionele segregatie en integratie. Er werden geen associaties geobserveerd tussen informatieverwerkingssnelheid en deze netwerkmaten. Wel liet de hoog-risicogroep een significant hogere globale efficiëntie zien dan de laag- en gemiddeld-risicogroepen, wat mogelijk het gevolg is van een compensatiemechanisme. Wijzigingen in functionele hersennetwerkorganisatie zijn mogelijk subtiel en alleen meetbaar in patiënten met ernstigere cognitieve bijwerkingen.

Het tweede deel van dit proefschrift bevat studies waarin MR technieken zijn onderzocht die mogelijk nieuwe inzichten in epilepsie en cognitie kunnen geven. **Hoofdstuk 5** beschrijft een studie waarin verschillende MRS methoden om glutamaatconcentraties te meten werden vergeleken. De sequenties PRESS en MEGA-PRESS worden beide vaak gebruikt om glutamaatconcentraties te meten, hoewel ze hier niet speciaal ontworpen voor zijn: PRESS wordt veel gebruikt om verschillende neurometabolietconcentraties te meten, maar kan geen GABA-concentraties meten. MEGA-PRESS is juist ontworpen om deze GABA-concentraties te meten. **Hoofdstuk 5** vergelijkt de accuraatheid, reproduceerbaarheid, en overeen-

stemming van glutamaatmetingen met deze sequenties. Fantoommetingen lieten een goede accuraatheid voor beide sequenties zien. De reproduceerbaarheid is getest in vijf gezonde proefpersonen, en bleek toereikend voor beide sequenties, hoewel beter voor PRESS dan MEGA-PRESS. De overeenkomst tussen PRESS en MEGA-PRESS was echter matig (r=0.4), wat mogelijk verklaard kan worden door de aanwezigheid van macromoleculen in het PRESS of MEGA-PRESS spectrum. Gebaseerd op deze studie concludeerden we dat MEGA-PRESS inderdaad gebruikt kan worden om GABA en glutamaatmetingen te combineren, hoewel met een lagere reproduceerbaarheid dan wanneer PRESS gebruikt zou kunnen worden.

Hoofdstuk 6 beschrijft een nieuwe methode om hersennetwerken te onderzoeken, gebaseerd op metabole informatie verkregen uit glutamaat, GABA, en N-acetylaspartaat metingen. Klinische studies bestuderen voornamelijk structurele en functionele breinnetwerken. Echter, hiermee wordt geen directe informatie over neuronale integriteit of neurotransmitterbalans verkregen, wat de oorzaak is van abnormale neuronale activiteit in epilepsie. Daarom introduceerden wij het 'neurotransmitternetwerk' concept. Gebieden in de hersenen werden verondersteld verbonden te zijn, als de correlatie tussen deze gebieden (gezien over de proefpersonen) significant was.

Dit concept is getest in vijftien gezonde proefpersonen en tien patiënten met cryptogene, lokalisatie-gebonden epilepsie. In de gezonde proefpersonen liet 21%, 19% en 26% van de mogelijke verbindingen een significante correlatie voor respectievelijk glutamaat, GABA en NAA zien. Deze verbindingen kunnen worden gezien als een 'metabool breinnetwerk'. Zowel de glutamaat, als de GABA netwerken van de epilepsiepatiënten hadden een hogere connectiviteit dan die van de gezonde proefpersonen. We concludeerden dat deze neurotransmitternetwerken en verhoogde neurotransmitterconnectiviteit in epilepsiepatiënten verder onderzocht zouden moeten worden om de kennis over epilepsie te vergroten.

Het proefschrift wordt afgesloten met een algemene discussie in **hoofdstuk 7**. Dit hoofdstuk geeft een overzicht van de belangrijkste bevindingen in dit proefschrift, bediscussieert de bevindingen in een breder geheel en geeft aanbevelingen voor vervolgonderzoek.

Valorization

Relevance

Thousands of MR studies have been performed to investigate functional brain networks and neurotransmitter concentrations. These studies are primarily performed in the fields of neurology, neurosciences and psychology. Two different aims can be distinguished in these studies: firstly, to increase the understanding of healthy or diseased brain functioning; and secondly, to detect biomarkers that might be used for diagnosis, to predict disease progression or treatment effects [1–3].

In this thesis, we focused on brain connectivity in epilepsy, and its relation to cognition. In the Netherlands, there are approximately 120,000 patients with epilepsy, and six-thousand new patients are diagnosed every year [4]. Epilepsy is often accompanied with cognitive problems, such as impaired memory, concentration, or slowed information processing speed [5]. These cognitive problems may be caused by the epilepsy itself, the underlying etiology, or as side effect of antiepileptic drug (AED) treatment. At this moment, neurologists have no objective means to predict who will develop adverse side effects or not.

We mainly focused on the effects AED treatment in this thesis. Cognitive side effects are among the least tolerated side effects for patients with epilepsy [6], and are an important reason to halt or change the AED treatment [7]. Besides a large burden for the patients, cognitive side effects are also accompanied with economic costs, including increased health care costs, productivity losses, and patients and family costs. The total societal costs of cognitive side effects are estimated to be around 7,000 € per patient per year in the Netherlands [8]. Better understanding of the relation between epilepsy, AED treatment, and cognition might help during clinical decision-making and ultimately improve treatment of patients with epilepsy.

Main findings

In the first part of this thesis, clinical studies are presented that assessed associations between AED use, cognition, and MR markers. We observed associations between decreased information processing speed and lower glutamate concentrations. These glutamate concentrations were also associated with AED use. The second part of this thesis described methodological studies to neurotransmitter

measurements. We compared two methods to measure *in vivo* glutamate concentrations using MR spectroscopy: PRESS and MEGA-PRESS. This study showed a good accuracy for both methods, although the repeatability was better in PRESS than MEGA-PRESS. Finally, we developed a method to assess 'neurotransmitter networks', and showed an increased glutamate and GABA connectivity in patients with epilepsy.

Target groups

First of all, the findings of this study are relevant for patients with epilepsy, as the findings might, in future, improve pharmacological treatment in epilepsy. This is also of interest for their neurologist, who might be better able to select proper treatment, and the pharmaceutical industry. Pharmaceutical applications of MRI are starting to develop, and MR markers might be beneficial to capture cognitive side effects or treatment efficacy in an early state, or to explore proper dose ranges [9].

The methodological part is mostly relevant for other researchers in the field of neurology, neurosciences and psychology, as it might aid new studies of the involvement of neurotransmitter levels in different neurological, psychological and psychiatric diseases. Therefore, other patients suffering from these diseases might benefit from these studies as well.

Innovation and future directions

The studies presented in this thesis should be considered as explorations on the interplay of MR methods and epilepsy, AED treatment, and cognition. While advanced MR imaging of epilepsy and its consequences is an emerging field, MR studies to study AED effects are relatively scarce and to our knowledge, the studies in this thesis are the first that associate AED use and cognitive functioning to respectively neurotransmitter levels and functional brain organization. The observed associations between glutamate levels and cognitive function might be useful as biomarker to predict which patient will suffer from cognitive side effects, and who will not. However, it is currently not known whether the differences in glutamate levels precede the cognitive problems or coincide with these problems. Therefore, longitudinal studies to this topic are required.

The main objective of the comparison between PRESS and MEGA-PRESS was to aid future clinical studies aiming to measure glutamate concentrations. In our study, we applied both PRESS, to measure glutamate concentrations, and MEGA-PRESS, to measure GABA concentrations. We showed that the glutamate

concentration could also be measured with MEGA-PRESS; comparable studies might therefore choose to only apply a MEGA-PRESS scan, and thereby shortening the scanning time.

Neurotransmitter networks, described in Chapter 6, are a newly introduced concept and might provide new possibilities to study brain function. Future studies should aim at a further evaluation of this concept. Optimization is still possible at the acquisition and the analysis stage of the data. Furthermore, the concept should be tested in larger groups and in different populations, such as children or elderly, or in different brain diseases.

References

[1] G. Öz, J. R. Alger, P. B. Barker, R. Bartha, A. Bizzi, C. Boesch, P. J. Bolan, K. M. Brindle, C. Cudalbu, and A. Dinçer. Clinical proton MR spectroscopy in central nervous system disorders. *Radiology*, 270(3):658–679, 2014.

[2] A. J. Ross and P. S. Sachdev. Magnetic resonance spectroscopy in cognitive research. *Brain Res Rev*, 44(2-3):83–102, 2004.

[3] C. Giessing and C. M. Thiel. Pro-cognitive drug effects modulate functional brain network organization. *Front Behav Neurosci*, 6:53, 2012.

[4] Epilepsiefonds. Bij wie en op welke leeftijd. https://www.epilepsie.nl/over-epilepsie/pagina/224-1/bij-wie-en-op-welke-leeftijd/.

[5] R. S. Fisher, B. G. Vickrey, P. Gibson, B. Hermann, P. Penovich, A. Scherer, and S. Walker. The impact of epilepsy from the patient's perspective I. descriptions and subjective perceptions. *Epilepsy research*, 41(1):39–51, 2000.

[6] J.-A. Witt, C. E. Elger, and C. Helmstaedter. Which drug-induced side effects would be tolerated in the prospect of seizure control? *Epilepsy & Behavior*, 29(1):141–143, 2013.

[7] H. P. Bootsma, L. Ricker, Y. A. Hekster, J. Hulsman, D. Lambrechts, M. Majoie, A. Schellekens, M. de Krom, and A. P. Aldenkamp. The impact of side effects on long-term retention in three new antiepileptic drugs. *Seizure*, 18(5):327–331, 2009.

[8] R. J. A. de Kinderen, S. M. A. A. Evers, R. Rinkens, D. Postulart, C. I. Vader, M. H. J. M. Majoie, and A. P. Aldenkamp. Side-effects of antiepileptic drugs: the economic burden. *Seizure*, 23(3):184–190, 2014.

[9] B. Wandschneider and M. J. Koepp. Pharmaco fMRI: Determining the functional anatomy of the effects of medication. *Neuroimage Clin*, 12:691–697, 2016.

Dankwoord

Zoals gebruikelijk wil ik in dit laatste hoofdstuk iedereen die heeft bijgedragen aan dit proefschrift bedanken. Sommigen hebben hele concrete bijdragen geleverd. Anderen stonden meer op de achtergrond, maar ook zonder hen had ik dit niet kunnen afronden.

Allereerst wil ik graag mijn promotieteam bedanken. Walter Backes, Bert Aldenkamp en Jaap Jansen, bedankt dat jullie mij de mogelijkheid hebben geboden voor dit promotieonderzoek, en voor jullie altijd betrokken en toegankelijke begeleiding. Dit heb ik als zeer prettig ervaren.

Walter, jouw feedback kwam meestal erg snel, soms zelfs sneller dan ik eigenlijk zou willen. Wat een luxe! Tegelijkertijd ben je altijd kritisch, maar ook erg betrokken bij jouw promovendi, wat volgens mij een goede promotor kenmerkt. Bert, jouw bijdrage was wat meer op de achtergrond, maar jouw ideeën over en de feedback op met name de klinische onderdelen zijn een grote bijdrage geweest aan dit proefschrift. Jaap, jouw deur stond altijd open en dit heb ik zeer op prijs gesteld. Je weet een kritische blik te combineren met een pragmatische aanpak. Dit laatste was voor mij soms wat wennen, maar daarmee ook erg leerzaam. Bedankt voor deze samenwerking!

Verder ben ik dank verschuldigd aan al mijn co-auteurs. Allereerst mijn dank aan Dominique: Wat heb jij hard gewerkt aan de AED studie! Ik heb bewondering voor jouw niet-aflatende energie en wil je veel succes wensen met jouw carrière. Rob Rouhl en Marielle Vlooswijk: Tien geschikte proefpersonen vinden bleek heel lastig te zijn, maar het is op het nippertje toch gelukt! Bedankt daarvoor, en zeker ook voor jullie kritische inbreng tijdens het onderzoek en schrijven van het artikel. Ook Paul Hofman, Richard Lazeron, Anton de Louw, Frank van Bussel, Tom Scheenen en Dennis Klomp dank ik voor hun inbreng. Finally, I would like to thank Richard Edden, Nick Puts, and Desmond Tse for their contribution as co-author.

Ook anderen hebben een essentiële bijdrage geleverd aan mijn onderzoek: Allereerst natuurlijk alle proefpersonen die hieraan meegewerkt hebben. Verder wil ik Remco Berting bedanken voor het scannen bij Kempenhaeghe, en Esther Steijvers en Lotty Huijboom voor het scannen bij Scannexus. Bedankt voor alle gezellige uurtjes achter de scanner! Voor het maken van de fantomen moet ik Ingrid Dijkgraaf en haar collega's bedanken, voor het beschikbaar stellen van hun labfaciliteiten.

Als laatste ben ik Jos en Marc veel dank verschuldigd voor alle computerfaciliteiten binnen de afdeling Radiologie, zonder welke ik niet alle analyses had kunnen uitvoeren.

Daarnaast wil ik mijn kamergenoten en collega's bedanken: René, voor het helpen aan het begin van mijn promotie; Frank, Harm en May voor al jullie advies én de gezellige uurtjes; en Gerald, Laura, Lisanne en Joost, bedankt voor de gezelligheid, en succes tijdens jullie verdere promoties/postdoc-periode! Als laatste wil ik al mijn overige collega's bij de afdeling Radiologie en bij Kempenhaeghe bedanken voor hun gezelligheid tijdens de lunch, borrels en de Kempenhaeghe-etentjes.

Ook een kort woord van dank aan mijn paranimfen May en Ingeborg. Waar ik bijna mijn gehele promotietijd een kamer met May heb gedeeld, heb ik tijdens vrijwel mijn hele studie samen met Ingeborg in één huis gewoond. Wat heb ik veel gezelligheid, maar ook frustraties met jullie kunnen delen: niet alleen over onze promoties, maar ook over alle andere dingen in ons leven. Fijn dat jullie naast mij willen staan tijdens mijn verdediging!

Mijn laatste woorden zijn voor de mensen die het dichtst bij mij staan. Papa en mama, hoewel jullie hadden gehoopt dat ik na mijn studie weer wat dichterbij zou komen wonen, hebben jullie mij altijd gesteund en aangemoedigd om te gaan promoveren in Maastricht. Bedankt dat jullie er altijd voor mij zijn. Lieve Fokke, we hadden nog maar net een relatie toen ik solliciteerde voor deze promotie. Mijn keuze om naar Maastricht te gaan heeft het ook voor jou niet makkelijker gemaakt, maar we hebben ons samen door de vele treinreizen heen geslagen. En hoewel voor ons beiden het 'Hora est' nog moet komen, durf ik al wel te stellen dat het ons gelukt is! Dank je wel!

Curriculum Vitae

Tamar Marije van Veenendaal was born in Nijkerk at March 6th, 1988. In 2000, she started secondary school at the Christelijk College Nassau-Veluwe in Harderwijk. After her graduation in 2006, she moved to Enschede to study Biomedical Engineering at Twente University, with as specialization Human Function Technology. During her master she did an internship at Aalborg University, Denmark in which she performed experiments to assess heat hyperalgesia in human participants. She received her master's degree in 2012, after finishing her thesis focused on the computational modeling of neuronal networks.

In 2013, she went to Maastricht University for her PhD research, which is described in this thesis. This research was performed within the School for Mental Health and Neuroscience (MHeNS) under supervision of prof. dr. ir. W.H. Backes, prof. dr. A.P. Aldenkamp, en dr. J.F.A. Jansen and in collaboration with the epilepsy center Kempenhaeghe. After her PhD, she will start working as software engineer for the High Tech division of Sogeti Nederland B.V.

List of publications

This thesis

T.M. van Veenendaal, D.M. IJff, A.P. Aldenkamp, P.A.M. Hofman, M.C.G. Vlooswijk, R.P.W. Rouhl, A.J. de Louw, W.H. Backes, J.F.A. Jansen, "Metabolic and functional MR biomarkers of antiepileptic drug effectiveness: a review", *Neuroscience & Biobehavioral Reviews*, 59:92–99, 2015.

T.M. van Veenendaal, D.M. IJff, A.P. Aldenkamp, R.H.C. Lazeron, N.A.J. Puts, R.A.E. Edden, P.A.M. Hofman, A.J. de Louw, W.H. Backes, J.F.A. Jansen, "Glutamate concentrations vary with antiepileptic drug use and mental slowing", *Epilepsy & Behavior*, 64:200–205, 2016.

T.M. van Veenendaal, D.M. IJff, A.P. Aldenkamp, R.H.C. Lazeron, P.A.M. Hofman, A.J. de Louw, W.H. Backes, J.F.A. Jansen, "Chronic antiepileptic drug use and functional network efficiency: A functional magnetic resonance imaging study", *World Journal of Radiology, In press.*

T.M. van Veenendaal, W.H. Backes, F.C.G. van Bussel, R.A.E. Edden, N.A.J. Puts, A.P. Aldenkamp, J.F.A. Jansen "Glutamate quantification by PRESS or MEGA-PRESS: accuracy, repeatability, and concordance", *Submitted.*

T.M. van Veenendaal, W.H. Backes, D.H.Y. Tse, T.W.J. Scheenen, D.W. Klomp, P.A.M. Hofman, R.P.W. Rouhl, M.C.G. Vlooswijk, A.P. Aldenkamp, J.F.A. Jansen, "High field imaging of large-scale neurotransmitter networks: proof of concept and initial application to epilepsy", *Submitted.*

Other publications

J. le Feber, T. Witteveen, T.M. van Veenendaal, J. Dijkstra, "Repeated stimulation of cultured networks of rat cortical neurons induces parallel memory traces", *Learning & memory*, 22(12):594–603, 2015.

D.M. IJff, T.M. van Veenendaal, H.J.M. Majoie, A.J.A. de Louw, J.F.A. Jansen, A.P. Aldenkamp, "Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy", *Acta Neurologica Scandinavica*, 131(6):347–354, 2015.

F.C.G. van Bussel, W.H. Backes, T.M. van Veenendaal, P.A.M. Hofman, M.P.J. van Boxtel, M.T. Schram, S.J.S. Sep, P.C. Dagnelie, N. Schaper, C.D.A. Stehouwer, J.E. Wildberger, J.F.A. Jansen, "Functional brain networks are altered in type 2 diabetes and prediabetes: signs for compensation of cognitive decrements? The Maastricht study", *Diabetes*, 65(8):2404–2413, 2016.

D.M. IJff, T.M. van Veenendaal, M.H. Debeij-van Hall, J.F.A. Jansen, A.J.A. de Louw, M.H.J.M. Majoie, A.P. Aldenkamp, "The Cognitive Profile of Ethosuximide in Children", *Pediatric Drugs*, 18(5):379–385, 2016.

G.S. Drenthen, E.M. Barendse, A.P. Aldenkamp, T.M. van Veenendaal, N.A.J. Puts, R.A.E. Edden, S. Zinger, G. Thoonen, M.P.H. Hendriks, R.P.C. Kessels, J.F.A. Jansen, "Altered neurotransmitter metabolism in adolescents with high-functioning autism", *Psychiatry Research: Neuroimaging*, 256:44–49, 2016.